Check for updates

Accepted Article

DR. MARTHA CABRERA (Orcid ID : 0000-0003-0944-5842)

DR. DERMOT RYAN (Orcid ID : 0000-0002-4115-7376)

DR. BERTINE MJ FLOKSTRA - DE BLOK (Orcid ID : 0000-0001-5356-764X)

Article type : Position Paper

Corresponding author mail id :- marthacs65@gmail.com

Title: Current allergy educational needs in primary care. Results of the EAACI working group on primary care survey exploring the confidence to manage and the opportunity to refer patients with allergy.

Short running title: Allergy educational needs in primary care in Europe.

Cabrera M[1], Ryan D[2], Angier E[3], Losappio L[4], Flokstra – de Blok B.M.J.[5,6,7], Gawlik R.[8] , Purushotam D[9], Bosnic-Anticevich S[10]

1. Allergy Department. Hospital los Madroños, Brunete. Madrid, Spain. 2. Usher Institute, University of Edinburgh, United Kingdom. 3. Primary Care and Population Sciences, University of Southampton, United Kingdom. 4. Allergy and Immunology Unit, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy. 5. General Practitioners Research Institute, Groningen, the Netherlands. 6. University of Groningen, University Medical Center Groningen, GRIAC Research Institute, Groningen, The Netherlands. 7. University of Groningen, University Medical Center Groningen, Beatrix Children's Hospital, Department of Pediatric Pulmonology and Pediatric Allergology, Groningen, The Netherlands. 8. Department of Internal Medicine, Allergology and Clinical Immunology, Silesian University of Medicine, Katowice Poland. 9. Mandore Sattelite Hospital. Jodhpur, India. 10. Quality Use of Respiratory Medicines Group, Woolcock Institute of Medical Research, University of Sydney, Australia.

Manuscript Acceptance Date: 28-Aug-2021

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1111/ALL.15084

This article is protected by copyright. All rights reserved

ACKNOWLEDGMENTS

The study was made possible by a grant from the executive committee of EAACI and the EAACI Communications and Marketing Department and Primary Care scientific Societies. Our thanks are extended to José Miguel Cárdenas Rebollo, Statistician Professor from the CEU University in Madrid Spain, who performed statistical analysis.

ABSTRACT:

The aim of this survey was to explore the specific educational needs of a cohort of European GPs with regards to allergy training so that future educational initiatives may better support the delivery of allergy services in primary care. Method: This study took the form of a cross-sectional observational study in which a structured electronic questionnaire was distributed to primary care providers, in eight languages, across 8 European countries between September 2019 and November 2019. Data associated with demographic parameters, professional qualifications, type of employment, level of confidence regarding competencies for diagnosis and treatment of allergic diseases, referral of patients to allergist and preferred method of learning and assessment were collected. A 5-point Likert scale was used to assess level of confidence. Exploratory analysis was carried out. Results: A total of 687 responses were available for analysis, with 99.3% of responders working within Europe. 70.1% of participants were female; and 48.0% and 48.0% of participants respectively had received some undergraduate and/or postgraduate allergy education. Confidence in dealing with different aspect of allergy management differed between countries. The main reason for specialist referral was a perceived need for tertiary assessment (54.3%) and the main barrier for referral was the consideration that the patient's condition could be appropriately diagnosed and treated in a primary care facility. Up to 44.7% and 55.3% of participants reported that they preferred e-Learning over traditional learning. Conclusions: This study identified the specific areas of skills training and educational needs of GPs in managing allergic conditions in primary care, and provided insights possible strategies for more feasible and cost-effective approaches.

KEY WORDS: education; allergy diagnosis; allergy treatment; learning methods; primary care.

INTRODUCTION

This article is protected by copyright. All rights reserved

Accepted Article

Over the last few decades, considerable advances have been made in our understanding of allergic diseases, particularly with regards to the aetiology of disease, underlying mechanisms (immunology), and clinical parameters such as approaches to diagnosis, and treatment. Allergic diseases pose a huge burden on individuals, the community, and the health care system.[1] Allergic diseases are highly prevalent and have been identified as a high burden public health problem which needs to be urgently addressed.[2] In addition, the associated direct and indirect health care costs of these diseases are extremely high.[3]

Despite this heterogeneity in allergy services have been identified [4] and few medical school faculties regard allergology as a specific and discrete subject area; consequently, undergraduate training in this field is deficient. Consequently, most people with allergic conditions are initially assessed by a primary care physician who may not be adequately skilled in the management of allergic diseases.[5, 6]

The World Allergy Organization (WAO) issued a warning concerning the gaps between knowledge and practice in the field of allergy management, subsequently presenting its position paper "Recommendations for Competency in Allergy Training for Undergraduates Qualifying as Medical Practitioners".[7] To date, there is little evidence of an appetite to incorporate allergy in the undergraduate curriculum.

In Europe, about 30% of the population suffer from an allergic disease and the prevalence is increasing.[8] Greater knowledge of allergic diseases by health care providers would be expected to result in more rapid diagnosis, more adequate treatment, and better quality of life for those who suffer from allergic diseases.[2]

Primary care (PC), which includes general practitioners (GP), family practitioners, family physicians or paediatricians, can reinforce its role in health care as the first point of contact for patients with allergic symptoms.[5] In fact, the need for primary care to be involved in the management is critical as in many areas of Europe[9], there are insufficient allergists to support the rising prevalence of allergies.[5,6] Herein lies the challenge; although PC providers are generally well trained, evidence suggests a deficiency of knowledge, skills and resources to independently manage patients with allergies independently with confidence. [5,6] Attempts to circumvent this barrier to allergy management have been developed and take the form of initiatives such as clinical algorithms[10] or allergy management support systems in primary care.[11] However, these initiatives do not address the fundamental issue of PC education of allergy at undergraduate and postgraduate levels, which clearly needs to be improved in order to improve outcomes.[7] In the UK a national allergy education strategy is being devised covering all health care professionals and this has the potential to be a basis for wider work across Europe.[12]

This article is protected by copyright. All rights reserved

The European Academy of Allergy and Clinical Immunology (EAACI) working group on PC recognizes the needs of our patients, health systems and the scientific community, to improve the quality of practice, incorporating a patient centred approach, developing integrated care models and better defining the role of PC in the diagnosis and management of allergic diseases. In line with the EAACI white paper strategy document[13], it is further recognised that there is a strong need to reinforce the collaboration and communication between primary care and specialized care for patients with allergic disease(s).

Although some regional scientific allergy societies and specialists have developed continuous medical education modules on this topic, for a consistent approach it is necessary to know and understand the needs perceived by primary care professionals.[6] A previous EAACI primary care working group survey on educational needs was carried out from June to September 2014 and the results were reported in 2017. In this study, self-declared gaps in knowledge were expressed for most manifestations of allergy with a correspondingly high self-expressed educational need.[14]

There is clearly a need to bridge the educational gaps of health care providers in PC. The explosion of allergy-related disorders coupled with their increased prevalence has left GPs feeling vulnerable, particularly as allergy appears to be virtually excluded from both undergraduate and postgraduate GP training[15], in spite of repeated calls for improved education to improve outcomes[16], with deficits being recognized across healthcare systems.[17] These concerns are shared with paediatricians, who are often the first point of call for children in many countries.[18] It is of note that one of the consequences of this skill and knowledge deficit is many unnecessary referrals to specialist clinics.[19] Work has also been undertaken to describe the core competencies required by GPs[20], allied health care providers[21], and those which might be needed to provide a specialized level in primary care (GP with a specialist interest in allergy (GPwSI)). GPwSIs are generally GPs who also work part-time in a defined clinical role. They see 7% of allergy referrals in the UK and have been instrumental in developing new models of care.[19, 22] In light of this, work has been undertaken to describe the core competencies required by GPs to provide allergy care and those which might be needed to provide a specialized level in primary care.[20]

The aim of this survey was to explore the specific educational needs of a cohort of European GPs with regards to allergy training so that future educational initiatives may better support the delivery of allergy services in primary care.

METHODS

This article is protected by copyright. All rights reserved

An electronic questionnaire was developed by the EAACI-WGPC (Working Group on Primary Care) in collaboration with the EAACI Marketing and Communications Department (A completed example attached as Annex S1). Questionnaire development was based on empirical evidence and expert opinion. The layout and accessibility of the different language versions of the questionnaires were centralized by this EAACI Department.

A structured questionnaire, administered through Survey Monkey (demographic parameters, professional qualification, type of employment, level of confidence regarding competencies for diagnosis and treatment of allergic diseases, referral of patients to allergist and preferred method of learning and assessment) was made available in eight languages (English, Dutch, Italian, Spanish, Greek, Polish, French and German) and distributed to eight different European countries during the period September to November 2019. Prior to dissemination, a pilot study was carried out in Spain (20 April to 5 May 2019) to test the functionality of the survey.

Distribution of the questionnaire to primary care health care professionals was enabled through regional GP scientific societies or GP networks. These varied across the different countries. Local participating Societies were emailed with the corresponding survey link, which was made available to PC providers through their local PC societies' websites with the aim of recruiting as many PC providers as possible (including nurses and other allied professions). All national colleges and associations of PC, which appear on the WONCA (World Organization of National Colleges, Academies and Academic Associations of General Practitioners/Family Physicians, Europe) website, were emailed in a bid to increase exposure (time to respond, reminders, etc).

Thirty surveys per participating country was the cut-off for inclusion and statistical analysis. Frequencies and percentages were calculated. The sample size is reflective of a convenience sample; the recruitment period was from September to November 2019. Participation and survey responses were anonymized. Given that this was a non-interventional study to understand clinician's educational needs, ethics committee approval was not sought. Participant confidentiality was been maintained.

The online questionnaire consisted of 18 items and an open field to include any additional comments, covering 6 domains (participant and practice demographic data, type of employment/practice, level of confidence (knowledge/skills), factors influencing referral/lack of referral to allergy specialist, access to allergen immunotherapy and preferred methods of learning) (Annex S1). Responders were asked to rate their confidence across several different areas of allergic disease management on a scale of 1 to 5, where 1 was no confidence and 5 was very confident. The investigators then classified a score of 4 or 5 to the

This article is protected by copyright. All rights reserved

label “confident” and scores 1, 2 or 3 to the label “not confident”, in order to aid analysis and facilitate interpretation.

Statistical analysis: descriptive analysis was carried out and summary statistics were produced (mean, standard deviation (SD), median and interquartile range (IQR; 25th and 75th percentiles) for the continuous variables, and counts and percentages for the categorical variables, respectively). Crosstabs relationship for a limited number of variables related to education related to education were performed using chi^2 test (level of confidence 95%) (learning and assessment method preference and age; education, learning and assessment preference and country)

RESULTS-

The e-questionnaire was successfully distributed to the targeted 8 countries. The countries from which a minimum of 30 responses were received were UK n=348, Spain n=133, The Netherlands n=57, Poland n=69 and Italy n=83, providing 690 responses for analysis. Responses received from allergists (n=56) were not included. Of the responses, 348 were in English and 341 in other languages. Three surveys were excluded based on members pilot study data, leaving a total number of 687 evaluable surveys in total. Table 1 summaries the overall characteristics of responders.

The majority of responders (54.2%) were aged between 35-54 years age ranges; 70.1% were female, 99.3% were working within Europe. The most common area of practice was “Primary Care Clinician” (67.9%, n=468). Most responders (68.2%, n=470) worked in a state or district health service, 11.2% (n=77) in private practice, 2.0% (n=14) at a university, college and 0.3% (n=20) were retired. A detailed summary of responder demographics is included in Table 1. A full demographic table appears in Annex S2.

A specialist interest in allergy was reported by 22.5% (n=155) of responders; and of those, 78.0% reported working 0-8hours/week in this field.

A majority of responders (64.7%, n=446) reported seeing between 0-10 patients per week whose main complaint was an allergic problem. Seventy percent (70.3%, n=484) of responders reported that less than half their patients visited a pharmacy exclusively prior to visiting them for their allergy within the previously year.

Overall 18.4% (n=127) of responders reported receiving no education associated with allergy: 48.0% (n=331) and 48.0% (n=331) receiving allergy training as undergraduates and postgraduates respectively. This varied greatly between different countries, with the highest proportion of responders receiving training in The Netherlands and Poland (Figure 1). There was also a large range in the proportion of

This article is protected by copyright. All rights reserved

responders who were aware of local GP guidelines for referral, with the highest awareness amongst responders in The Netherlands (89.5%) and the lowest amongst those from Italy (24.1%) (Figure 2). A low proportion of responders from all countries were aware of the EAACI competencies for Allergy Health Professionals (AHP) for allergy (range 1.8% in The Netherlands to 13.2% in the UK) (Figure 2). There was a statically significant difference between knowledge of the EAACI competencies document for AHP ($Chi^2p=0.001$, n=516) across the different countries (Annex S5).

Table 2 summaries the proportion of responders with "Adequate" confidence in managing different allergic conditions. Overall responders felt most confident to manage rhinitis/asthma (83.3%), and least confident to manage occupational allergy (23.5%) (Annex S3). When it came to confidence in understanding the basic management principles underpinning the treatment of allergic rhinitis, anywhere between 47.3% and 83.8% of responders did not feel adequately confident in understanding sensitisation, cross-reactivity, basic mechanisms, immunotherapy and environmental control measures (Annex S3); while 56.2% and 50.0% felt adequately confident to provide advice on risk assessment for anaphylaxis and prescription/training in adrenaline use respectively (Annex S3). Responders were least confident in managing anaphylaxis, food allergy, drug allergy, latex allergy, occupational allergy and venom allergy.

With regards to referral to an allergist, 43.8% of responders felt confident in identifying patients who need a referral. Figure 3 summarises the factors influencing the responder's decision to refer to a specialist (Annex S3). Although the importance of the different factors for referral to an allergist varied from country to country, in all countries the most important factor identified was "Need for hospital assessment" ie need for specialist assessment (ranging from 29% to 78.9% of responders) and the least influencing factor being "Lack of knowledge of the patient's condition" (ranging from 2.9% to 32.3%). The greatest barrier to referral was the perception that the patient's condition could be diagnosed and treated in primary care (51.4%) and 15.8% felt there was long waiting time for the specialist. Figure 3 summaries the difference between countries with regarding to referral. Ten percent (10.6%) of responders did not refer to an allergist because there was no allergist in the area/health system (Figure 4); 52.6% did not refer as they considered that the patient's condition could be treated in primary care (Figure 4).

There was a statistically significant difference between the different countries with regards to access to fundamental investigations ($Chi^2p=0.000$, n=517) (Figure 5). Thus, specialist referral provided access to investigations. Less than half the responders from the UK, Poland and Italy reported having access to immunotherapy; approximately half in Spain (54.8%) and a majority in the Netherlands (87.7%) (Figure 5).

This article is protected by copyright. All rights reserved

To the item "there are no allergists in my Area/Health System", the lowest rate was for Spain (0.8%), and the highest for Italy 14.5% (global 10.8% across Europe) (Figure 5).

Learning preferences for responders is summarised in Figure 6. There was a statistically significant difference across the different age groups with regards to a preference for traditional versus e-learning with responders aged 35-54 years old preferring e-learning over traditional learning relative to the young and older aged responders (Chi^2 p=0.004, n=513) (Table 3). Computers were the preferred platform for learning (Table 3), Annex S4.

DISCUSSION

The aim of this multi-national cross-sectional survey was to explore the specific educational needs of a cohort of European GPs with regards to allergy training. It was identified that there continues to be unmet need for primary care (PC) providers to be upskilled in the management of allergy across all aspects of allergy management, from education to reasons for referral to an allergist.

Firstly with regards to fundamental training at the undergraduate and postgraduate level, less than half the responders reported receiving allergy education at undergraduate level and almost 1 in 5 had not received any training on allergic disease at either undergraduate or postgraduate level. This is clearly unacceptable given the high prevalence of allergic disease and the complexity of the field of medicine as well as the subsequent high exposure of not only medical PC providers, but also allied health care providers, to patient with allergy. PC providers are increasingly required to be involved in allergy care and prevention, helping to ensure optimal care and provide needed reassurance, personalized education, and ongoing therapeutic support in order to help patients of all ages to balance safety with normal living. It is therefore important to ensure that all patients and families living with an allergy have access to a PC providers, across the health care disciplines including nurses, dietitians, psychologists, pharmacists and other important AHP, so that holistic care can be provided and that referrals to both GPs and allergist can be appropriate supported. The need for an integrated approach has been recognised[21, 23] and with core competencies for primary care providers already having been proposed[20, 21], the next step would be for a global blueprint for allergy education for PC providers from undergraduate to continuing professional education levels to be developed.

This need for education is further reflected in the confidence levels reported by responders across the different countries. Overall, while the confidence level in different countries and across the different

This article is protected by copyright. All rights reserved

allergic conditions varied, overall confidence levels were low. Consistent with previous literature[14], the overall confidence level of management of allergic conditions such as rhinitis/asthma, eczema/atopic dermatitis/anaphylaxis, anaphylaxis and urticaria/angioedema was higher than for other allergic conditions. While we were not able to determine whether this confidence was well founded ie we can not determine whether confidence is reflective of competence, it would appear there still remains a gap between how allergic conditions are being managed in real life. Just taking the example of allergic rhinitis, which was reported to be managed with 'adequate' confidence by responders, in real life about only 15% of people with allergic rhinitis are optimally treated[24] and over 50% of people with asthma live with poorly controlled allergic rhinitis[25] supporting the need for education across all allergic conditions and related comorbidities.

A very low number of responders were aware of EAACI competency guidelines, highlighting the need for improved dissemination of global strategies and frameworks specifically to penetrate PC colleges, organisations and networks and to identify and develop PC leaders and champions for allergy. When it comes to the possible mechanisms to enable this, both traditional and e-learning methods were preferred across different age groups. However e-learning may be the most feasible solution, from the perspectives of logistics, accessibility and acceptability especially more recently with the constraints of the pandemic. Many societies and education and conference providers have now developed user friendly platforms that can support this. Over half the study participants, slightly preferred e-learning to traditional methods, while categorisation of preferred learning methods across different ages groups indicated that there was only an overwhelming preference for traditional learning techniques in a very small of responders ie >65 years of age and a moderate preference in the 55-64 years old, who together made up about one quarter of the sample. While these results may reflect the study sample it is important to recognise that this sample was already a group of individuals who are willing to engage in online platforms, thereby participated in this online survey. Further when divided by country, there are marked difference in the way in which PC professionals from different countries preferred to receive education (for example, in Spain half the participants reported a preference for e-learning whereas in Poland less than 1 in 5 preferred this method. It should be noted that this survey was performed before epidemic COVID-19 and applies to question and replies relating to e-Learning and on-line assessment. This may have impacted on the result with regards to preferred platforms of learning.

Another important aspect of this study is related to the process of referral to specialists. Most responders were not aware of local country guidelines for referral and therefore, it is perhaps not surprising that the majority of respondents in that study expressed a great lack of confidence in identifying patients needing

This article is protected by copyright. All rights reserved

referral, and this was more apparent for allergen immunotherapy, suggesting even greater lack of familiarity/access to this treatment, consistent with precious findings.[26, 27] Despite this lack of confidence, the main reason for not referring was because responders felt that the patient could be managed in primary care; followed by the lack of access to allergists. The latter is a major problem in some countries, where referral to an allergist can take beyond 6 weeks[1]. In contrast the main reason for referral was due to the need for allergist confirmation of condition and management or because of recognised lack of knowledge. There seems to be somewhat of a tension between the responses to different aspects of referral once again highlighting the need for better education and support for PC professionals in their decision making around allergy. Failure to have this critical need fulfilled is reflected in inappropriate referral levels to specialist clinics.[27] Developing a cohort of GPwSIs, particularly in countries where there is a deficit of allergists may offer a solution whereby shared care protocols for continuation of therapy commenced by specialists in general practice may be used.

We observed several differences of note across countries and this is most likely reflective of the different health care systems. This is exemplified in the access to different allergy investigations and immunotherapy across the different countries. This has previously been identified.[28, 29] For example, in Italy, one of the European countries with the highest counts of allergists[30], few GPs initiated or administered immunotherapy because the majority of immunotherapy was prescribed/administer when the patient is under the care of an allergist or being treated in a specialist unit. Very few GPs in the UK initiate immunotherapy and the same pertains to Spain and Netherlands. Another difference was noticed in confidence levels reported and noted earlier, with higher confidence being reported amongst Dutch PC professionals, followed by those in Poland. PC providers in The Netherlands also reported far greater access to allergy tests, immunotherapy coupled with high access to allergists, suggesting that in The Netherlands, allergy is treated in PC to a far greater extent that in other countries, consistent with PC professionals in The Netherlands having greater awareness of national primary care food hypersensitivity guidelines.[31.] The possible explanations for this are complex and can only be hypothesised at this point, but it is possible that overall, there is a more concerted approach to supporting PC providers as the custodians of both acute and chronic illnesses in The Netherlands, and this includes the management of allergic conditions. Overall, it does appear that they are more involved themselves in the evolution of pathways and guidelines. Shared care models for allergy immunotherapy have been successful in Finland where primary care workers spend time in specialist units then form 'hub and spoke 'models with specialist units.

This article is protected by copyright. All rights reserved

In considering the implications of these results, it is important to consider the limitations, the study population and the timing of this research. It is possible that this group of PC providers is bias towards those with and interest in allergy and those who are willing to engage with online platforms. In addition, about one fifth actually said they had a special interest in allergy and over half saw fewer than 10 patients with allergy per week, with one fifth seeing up to 25 per week; we can not verify the representative nature of these experiences. There was an uneven distribution of PC professionals from the different countries, probably as a failure of awareness of the study amongst those who were not interested in allergy or respiratory disease; it was not possible to continue to recruit until equal representation from each country was achieved. In order to address the implications of these results, we have attempted to identify and report on outliers amongst the different countries. Further we recognise that, with this study having been conducted prior to COVID-19, the responses to these questions might be different were this research conducted post COVID 19.

In conclusion, there are several clear messages that come out of this research.

Key findings:

1. There is inadequate allergy training of PC providers at the undergraduate and postgraduate level.
2. There is an overall lack in PC provider confidence in management of certain allergic conditions, understanding the basic principles underpinning key allergy process and in providing advice relating to anaphylaxis and adrenaline use.
3. There is variability across different European countries with regards to many aspects of allergy training, confidence and management
4. While there is some awareness of local allergy guidelines for PC providers, there is minimal awareness of EAACI guidelines across all countries.

Recommendations:

1. Even though the confidence level primary care providers in some areas of allergic disease management is high, the management of allergic diseases in primary care is suboptimal, therefore strategies/educational opportunities and tools to support primary health care providers across the spectrum of allergic diseases management should be developed.
2. Specific guidelines for the management of allergic conditions by PC providers need to be developed and disseminated across the different PC provider groups, including allied health care providers.

This article is protected by copyright. All rights reserved

3. Any guidelines for PC providers need to be developed under the assumption that many PC providers will not have received allergy training or are lacking in adequate confidence to treat the full spectrum of allergic conditions.
4. Any guidelines pertaining to primary care need to include representatives of primary care who have better knowledge of care barriers than many of their specialist colleagues
5. A country-specific approach is the key to the dissemination of allergy guidelines for PC providers.
6. EAACI needs to work with National Societies to instil the need to utilise any globally developed guidelines for PC providers and for them to be incorporated into undergraduate curricula across Europe as a minimum standard of health education
7. Service development should include increased clinical provision coupled with research to identify optimum means of providing effective and cost-effective approaches to managing allergic diseases in PC settings, including upskilling of GPs and use of telemedicine for screening/risk stratification running by a GP with a specialist with an interest in allergy, linked to a regional allergy service for specific queries
8. Short courses and practical training in allergy units for example in skin prick testing and immunotherapy could be considered to gain the necessary skills to then evolve into hub and spoke models with agreed quality standards of care across care settings.
9. EAACI or another provider could consider a bespoke exam and certificate of competence for primary care which would be based on theoretical knowledge and include a practical course which could be at local allergy centres thus improving relationships locally and there could be a register or map of interested primary care workers referring into and supporting specialist units
10. At this time it is critical that EAACI take leadership in supporting the role of primary care providers in the management of allergic diseases. This involves not only the establishment of training frameworks, competency standards and practice-based tools, but the development of care pathways which support primary care providers, across the spectrum of professions to better identify, triage and refer patients with allergic disease to appropriate care.

CONCLUSIONS:

The management of allergic conditions in primary care is complex and while important role of primary care is recognised at the highest of levels, GPs lack confidence in the full breadth of allergic disease management. Training in allergic diseases at undergraduate and postgraduate levels needs to be provided. Given the rapidly changing face of allergic diseases, this survey has enabled us to identify what the educational priorities of GPs are and how they would like to have them met. In the post COVID era

This article is protected by copyright. All rights reserved

Accepted Article

many aspects of education are now being delivered and designed on online interactive platforms and this medium lends itself well to primary care workers. If, as has been acknowledge, the time to address the significant gaps in the management of allergic conditions is now critical, the solutions must involve primary care providers, who are currently unsupported and sub-optimally equipped to address these challenges.[28] A strategy for primary care providers in the management of allergic conditions is needed now.

Accepted Article

This article is protected by copyright. All rights reserved

Accepted Article

REFERENCES

1. Pawankar R. Allergic disease and asthma: a global public health concern and a call to action. World Allergy Organization Journal. 2014;7(12):1-3.
2. Sanchez-Borges M, Martin BL, Muraro AM, Wood RA, Agache IO, Ansotegui IJ, et al. The importance of allergic disease in public health: an iCAALL statement. World Allergy Organ J. 2018;11(1):8.
3. Zuberbier T, Simoens JLS, Subramanian SV, Church MK. Economic burden if unadequate management of allergic diseases in the European Union: a GA2LEN review. Allergy. 2014;69(10):1275-9.
4. Fyhrquist N, Werfel T, Bilo MB, Mulleneisen N, Gerth van Wijk R. The roadmap for the Allergology specialty and allergy care in Europe and adjacent countries. An EAACI position paper. Clin Transl Allergy. 2019;9:3.
5. Agache I, Ryan D, Rodriguez MR, Yusuf O, Angier E, Jutel M. Allergy management in primary care across European countries -- actual status. Allergy. 2013;68(7):836-43.
6. Ryan D, Grant-Casey J, Scadding G, Pereira S, Pinnock H, Sheikh A. Management of allergic rhinitis in UK primary care: baseline audit. Prim Care Respir J. 2005;14(4):204-9.
7. Potter PC, Warner JO, WPawankar R, LKaliner MA, De; Giacoo S, Rosenwasser L. Recommendations for Competency in Allergy Training for Undergraduates Qualifying as Medical Practitioners: A Position Paper of teh World Allergy Organization. Journal of Investigational in Allergology and Clilnical Immunology. 2010;20(3):179-84.
8. Blomme K, Tomassen P, Lapeere H, Huvenne W, Bonny M, Acke F, et al. Prevalence of Allergic Sensitiation versus Allergic Rhinitis Symptoms in an Unselected Population. Internal Archives of Allergy and Immunology. 2013;160:200-7.
9. Khaleva E, Vazquez-Ortiz M, Comberiati P, DunnGalvin A, Pite H, Blumchen K, et al. Current transition management of adolescents and young adults with allergy and asthma: a European survey. Clin Transl Allergy. 2020;10:40.
10. Demoly P, Chabane H, Fontaine JF, de Boissieu D, Ryan D, Angier E, et al. Development of algorithms for the diagnosis and management of acute allergy in primary practice. World Allergy Organ J. 2019;12(3):100022.
11. Bertine MJ, Flokstra-de Blok BM, van der Molen T, Christoffers WA, Kocks JW, Oei RL, et al. Development of an allergy management support system in primary care. J Asthma Allergy. 2017;10:57-65.

This article is protected by copyright. All rights reserved

12. Vance G, Lydman S, Angier E, Kelman M, Denton S-A, Wright K, et al. Time to act to solve gaps in practice: The BSACI National Allergy Education Strategy. Clinical and Experimental Allergy. 2021;51:6-8.
13. Agache I, Akdis CA, Chivato T, Hellings P, Hoffman-Sommergruber K, Jutel M, et al. EAACI White Paper on Research, Innovation and Quality Care. 2018.
14. Ryan D, Angier E, Gomez M, Church D, Batsiou M, Nekam K, et al. Results of an allergy educational needs questionnaire for primary care. Allergy. 2017;72(7):1123-8.
15. Shehata Y, Ross M, Sheikh A. Undergraduate allergy teaching in a UK medical school: mapping and assessment of an undergraduate curriculum. Prim Care Respir J. 2006;15(3):173-8.
16. Grabenhenrich L, Hompes S, Gough H, Rueff F, Scherer K, Pfohler C, et al. Implementation of anaphylaxis management guidelines: a register-based study. PLoS One. 2012;7(5):e35778.
17. Kastner M, Harada L, Waserman S. Gaps in anaphylaxis management at the level of physicians, patients, and the community: a systematic review of the literature. Allergy. 2010;65(4):435-44.
18. Convers KD, Slavin RG. Attitudes toward allergy: what do the pediatricians think? Ann Allergy Asthma Immunol. 2014;113(5):544-8.
19. El-Shanawany IR, Wade C, Holloway JA. The impact of a General Practitioner-led community paediatric allergy clinic: A service evaluation. Clin Exp Allergy. 2019;49(5):690-700.
20. Wallengren J. Identification of core competencies for primary care of allergy patients using a modifield Delphi technique. BMC medical education. 2011;11(12).
21. Skypala IJ, de Jong NW, Angier E, Gardner J, Kull I, Ryan D, et al. Promoting and achieving excellence in the delivery of Integrated Allergy Care: the European Academy of Allergy & Clinical Immunology competencies for allied health professionals working in allergy. Clin Transl Allergy. 2018;8:31.
22. Allen HI, Vazquez-Ortiz M, Murphy AW, Moylett EM. De-labeling penicillin-allergic children in outpatients using telemedicine: Potential to replicate in primary care. J Allergy Clin Immunol Pract. 2020;8(5):1750-2.
23. Jutel M, Papadopoulos NG, Gronlund H, Hoffman HJ, Bohle B, Hellings P, et al. Recommendations for the allergy management in the primary care. Allergy. 2014;69(6):708-18.
24. Tan R, Cvetkovski B, Kritikos V, Price D, Yan K, Smith P, et al. Identifying the hidden burden of allergic rhinitis (AR) in community pharmacy: a global phenomenon. Asthma Research and Practice. 2017;3(1).

Accepted Article

This article is protected by copyright. All rights reserved

25. Bosnic-Anticevich S, Kritikos V, Carter V, Yan KY, Armour C, Ryan D, et al. Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed-dose combination therapy in Australia. J Asthma. 2018;55(6):684-94.
26. Conlon NP, Abramovitch A, Murray G, O'Hanrahan A, Wallace D, Holohan K, et al. Allergy in Irish adults: a survey of referrals and outcomes at a major centre. Ir J Med Sci. 2015;184(2):349-52.
27. Jones RB, Hewson P, Kaminski ER. Referrals to a regional allergy clinic - an eleven year audit. BMC Public Health. 2010;10:790.
28. Ryan D, Gerth van Wijk R, Angier E, Kristiansen M, Zaman H, Sheikh A, et al. Challenges in the implementation of the EAACI AIT guidelines: A situational analysis of current provision of allergen immunotherapy. Allergy. 2018;73(4):827-36.
29. Hannachi F, Demoly P, Chiriac AM, Bourrain JL, Dhivert-Donnadieu H, Costa D, et al. La place, en médecine générale, des nouveaux traitements d'immunothérapie allergénique sublinguale aux pollens de graminées chez les patients souffrant d'allergies respiratoires. Revue Française d'Allergologie. 2015;55(8):506-16.
30. Canonica GW, Cox L, Pawankar R, Baena-Cagnani CE, Blaiss M, Bonini S, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6.
31. Luning-Koster MN, Lucassen PL, Boukes FS, Goudswaard AN. Dutch College of General Practitioners' practice guideline can be more firm - the food allergy test does not exist. Ned Tijdschr Geneeskd. 2011;155(18):A3063.

Accepted Article

This article is protected by copyright. All rights reserved

FIGURE LEGENDS

Figure 1: Proportion of responders and allergy-related education received.

Figure 2: Proportion of responders' aware of local general practitioner (GP) referral guidelines and EAACI competencies framework.

Figure 3: Proportion of responders and reasons for referral to an allergist.

Figure 4: Proportion of responders' and reasons not to referring to an allergist.

Figure 5: Proportion of responders with access to allergy management resources.

Figure 6. Proportion of responders' learning and assessment preference.

(country names identified by colours).

APPENDICES

Supporting information are included in separated excel files.

DATA AVAILABILITY STATEMENT

The data that supports the findings of this study are available in the supplementary material of this article.

AUTHOR CONTRIBUTIONS

All the authors are members of the EAACI Working Group on Primary Care

The Task Force on Allergy Educational Needs in Primary Care conceived and designed the study protocol. MC, DR, EA, BF, RG, LL, SB and PD developed the concept. MC, DR, EA performed literature search and assessed study detail. MC, DR, EA, BF, LL, RG, NL contributed to acquisition of data. JMCR and MC checked data quality. MC, DR, EA, BF, LL and RG contributed to interpretation of results. MC, DR and SB wrote the first draft of the manuscript, which was critically revised by all the other authors. All authors approved the final version of the manuscript.

CONFLICTS OF INTEREST

Dr. Cabrera: EAACI financial supported the program.

Dr. Ryan reports personal fees from Regeneron, personal fees from AZ, personal fees from Novartis, personal fees from MEDA, personal fees from GSK, personal fees from Medscape, outside the submitted

This article is protected by copyright. All rights reserved

Accepted Article

work; and Board member Primary Care Interest Group, EAACI. Respiratory Effectiveness Group Vice-President. Member All Party Parliamentary Group, Respiratory Health, UK Parliament.

Dr. Angier has nothing to disclose.

Dr. Laura Losappio has nothing to disclose

Dr. Purushotam has nothing to disclose.

Dr. Flokstra - de Blok has nothing to disclose.

Dr. Gawlik has nothing to disclose.

Dr. Bosnic-Anticevich reports grants from TEVA, personal fees from TEVA, personal fees from TEVA, personal fees from AstraZeneca, personal fees from AstraZeneca, personal fees from Boehringer Ingelheim, personal fees from Boehringer Ingelheim, personal fees from GSK, personal fees from Sanofi, personal fees from Mylan, outside the submitted work.

Accepted Article

This article is protected by copyright. All rights reserved

Accepted Article

Current allergy educational needs in primary care. Results of the EAACI working group on primary care survey exploring the confidence to manage and the opportunity to refer patients with allergy.

TABLES

This article is protected by copyright. All rights reserved

Accepted Article

Table 1: Responder Characteristics

Characteristic			n	%
Age Group (categorized)		18 - 24	3	0.4
		25 - 34	127	18.4
		35 - 44	187	27.1
		45 - 54	189	27.4
		55 - 64	151	21.9
		65+	32	4.6
		Total	689	100
Gender		Female	483	70.1
		Male	206	29.1
		Total	689	100
Country of Employment (Europe)		Yes	684	99.3
		No	5	0.7
		Total	689	100
Qualification	GPs Current employment	GPs	468	67.9
		GPs with a special interest	34	4.9
		General medical specialist	31	4.5
	Nurses (current employment)	Primary Care Nurse	16	2.3
		General Nurse	6	0.9
		Allergy Specialist Nurse	11	1.6
	Other	Dietician	28	4.1
		Pharmacist	2	0.3
Further Specialist Qualification		MD	565	82
		Nursing diploma	56	8.1
		Pharmacist	4	0.6
		Other	62	9
Language		English	348	50.5
		Other (List of the four more language versions)	341	49.5
		Total	689	100
GPs main employer		State or District Health System	470	75.6

This article is protected by copyright. All rights reserved

Accepted Article

	Private	77	12.4
	University, collage or equivalent	14	2.3
	Retired	2	0.3
	Other	59	9.4

This article is protected by copyright. All rights reserved

Table 2. Self-perceived knowledge levels of confidence and educational needs

Condition	Reported confidence				UK n=241	Spain n=104	The Netherlands n=52	Poland n=41	Italy n=75
	n	Median (IQR)	Adequate%	Inadequate%	Median (IQR)				
Rhinitis/Asthma	532	4 (4,5)	83.3	16.7	4 (4,5)	4 (4,5)	4 (4,5)	4 (4,5)	4 (3,5)
Eczema/atopic dermatitis	530	4 (3,5)	66.4	33.6	4 (3,5)	4 (3,5)	4 (4,5)	4 (3,4)	4 (3,5)
Anaphylaxis	503	4 (4,5)	78.7	21.3	5 (4,5)	4 (4,5)	4 (4,5)	4 (4,5)	3 (2,5)
Contact dermatitis	528	4 (3,4)	61.2	38.8	4 (3,4)	4 (3,4)	4 (3,4)	3 (3,4)	4 (3,5)
Drug reaction/allergy	525	3 (3,4)	43.4	56.6	3 (2,4)	3 (3,4)	3 (3,4)	3 (3,4)	3.5 (2,5)
Urticaria/Angioedema	531	4 (3,5)	68.5	31.5	4 (3,5)	4 (3,5)	4 (4,5)	4 (4,4)	4 (3,5)
Food allergy	538	3 (3,4)	40.7	59-3	3 (3,4)	3 (3,4)	3 (2,4)	3 (3,4)	3 (3,4)
Latex allergy	502	3 (2,4)	32.9	67.1	3 (2,4)	3 (2,4)	3 (3,4)	3 (2,3)	3 (2,4)
Occupational allergy	490	3 (2,3)	23.5	76.5	3 (2,3)	3 (2,3)	3 (3,3)	3 (2,4)	3 (1,4)
Venom Allergy	453	3 (2,4)	37.3	62.7	2 (1,4)	3 (2,4)	4 (3,4)	4 (3,4)	3 (2,4)

Perceived confidence levels of 4 or 5 were categorised as “Adequate”; 1, 2 or 3 were categorised as “Inadequate”.

Accepted Article

This article is protected by copyright. All rights reserved

Table 3. Preferred methods of learning and assessment.

Age	Preference ratio (Traditional: e-learning)	E-platform by order of preference
18-24	100:0	Smartphone = Table = computer
25-34	59:41	Computer>Smartphone>Table
35-44	48:52	Computer>Smartphone>Table
45-54	48:52	Computer>Tablet>Smartphone
55-64	66:34	Computer>Tablet>Smartphone
+65	73:27	Computer>Tablet>Smartphone
TOTAL	55:45	Computer>Tablet>Smartphone

Accepted Article

This article is protected by copyright. All rights reserved

Accepted Article





Figure 1_Cabrera et al.

This article is protected by copyright. All rights reserved

Accepted Article



This article is protected by copyright. All rights reserved

Figure 2_Cabrera et al.

all_15084_f2.png

Accepted Article




Figure 3_Cabrera et al.

all.15084.f3.png

This article is protected by copyright. All rights reserved

Accepted Article




Figure 4_Cabrera et al.

all_15084_f4.png

This article is protected by copyright. All rights reserved

Accepted Article





Figure 5_Cabrera et al.

all_15084_f5.png

This article is protected by copyright. All rights reserved

Accepted Article



This article is protected by copyright. All rights reserved

Figure 6_Cabrera et al.

all_15084_f6.png

A survey on allergy diagnosis and treatment in Primary Care proposed by EAACI Primary Care Working Group

Allergic diseases prevalence is increasing worldwide, with 30% to 40% of the total population suffering from at least one form of allergy, such as allergic asthma or rhinitis, food allergy or atopic dermatitis. Primary Care has an important role first point of contact for patients with allergic symptoms. A previous EAACI Primary Care Working group survey on educational needs was carried out from June to September 2014, which results were reported in 2017. As diagnosis and management of allergic diseases are in constant evolution, the Board would like to update current educational needs from European GP's.
We propose a questionnaire to help identify how we can better assist you in the management of allergic diseases and assess your interest in allergy and your educational needs on this topic. In recognition of your time and effort, you will be entered into a draw to win a prize of free registration to the 2020 EAACI congress (see end of questionnaire). The final date for submission is 31 October 2019.

I do not wish to be assessed $\frac{1}{2\pi}$

(I do not wish to be assessed in which case the question does not appear, or I do wish to be assessed in which case the questions above appear).

Section 1 -

1.1 Personal Details

Age:---

Gender
1. Female
2. Male

Country: ---

1.2 Professional Qualifications

Primary Qualification
1. Medical Doctor
2. Nursing Diploma
3. Pharmacy Degree/Doctorate
4. Other (please specify)
5. Other

Area of practice (these do not all apply to every country)
1. Primary Care Clinician
2. Primary Care Clinician with an interest in allergy
3. General Medical Specialist
4. Allergist
5. Paediatrician
6. Paediatric Allergist
7. General Nurse
8. Primary Care Nurse
9. Allergy Specialist Nurse
10. Dietician
11. Pharmacist
12. Other

Section 2. Type of employment.

2.1 In the case of being a GP with specialist interest in allergy, how many hours a week do you work in this?

1. I am not a GP with specialist interest in allergy
2. 0-8 hs
3. 8-16 hs
4. 16-24 hs
5. 24-32 hs
6. 32-40 hs

2.2 Your Practice is within: (main Employer)

1. Contracted to State or District Health Service
2. Private Practice
3. University, College or Equivalent
4. Retired, not currently working
5. Other

2.3 How many patients per week come to see you whose MAIN complaint is an allergic problem?

1. 0-10
2. 11-25
3. 26-50
4. 50-100
5. >100

2.4 By your estimation, what percentages of patients with allergy have visited the pharmacy exclusively prior visiting you at your Primary Care facility in a year?

1. 0-10 %
2. 11-25 %
3. 26-50 %
4. 50-100 %
5. Don't know

2.5 Training, teaching allergy signature had you received as either undergraduates or post graduates studies?

2.5.1 I have received allergy teaching as undergraduate (theoretical and practical contents) Yes ❑ No ❑

2.5.2 I have received allergy teaching as post-graduate (theoretical and practical contents) Yes ❑ No ❑

Section 3. Level of Confidence

3.1 Regarding patients with a possible diagnosis of allergic disease, how confident are you in: (No Confidence 1 2 3 4 5 Very Confident) in making a diagnosis

		1	2	3	4	5	I do not see patients with this condition
Identifying allergic disease based on clinical presentation	Anaphylaxis	❑	❑	❑	❑	❑	❑
	Rhinitis/Asthma	❑	❑	❑	❑	❑	❑
	Atopic Dermatitis	❑	❑	❑	❑	❑	❑
	Contact Dermatitis	❑	❑	❑	❑	❑	❑
	Urticaria and Angioedema	❑	❑	❑	❑	❑	❑
	Food Allergy	❑	❑	❑	❑	❑	❑
	Drug Allergy (immediate and delayed)	❑	❑	❑	❑	❑	❑
	Venom Allergy	❑	❑	❑	❑	❑	❑
	Occupational allergy	❑	❑	❑	❑	❑	❑
	Latex allergy	❑	❑	❑	❑	❑	❑
The basic management principles underpinning the treatment of allergic disease	Understanding of terms like sensitisation, atopy, type I and type IV allergy	❑	❑	❑	❑	❑	❑
	Understanding cross-reactivity	❑	❑	❑	❑	❑	❑
	Basic mechanisms of allergic and non-allergic rhinitis and organic disorders for example in the nose and sinus.	❑	❑	❑	❑	❑	❑
	Pharmacologic Therapy (Basic mechanisms of common drugs for inflammatory disorders in airways and in skin.	❑	❑	❑	❑	❑	❑
	Immunotherapy	❑	❑	❑	❑	❑	❑
	Environmental Control Measures	❑	❑	❑	❑	❑	❑
Providing advice on the management of allergic disease	Risk assessment for anaphylaxis	❑	❑	❑	❑	❑	❑
	Prescription/training of adrenaline	❑	❑	❑	❑	❑	❑
Identifying patients who need to be referred to an allergist		❑	❑	❑	❑	❑	❑

3.2 What factors influence your decision to refer to a specialist (more than one option possible):

3.2.1 Are you aware of GP guidelines which include guidelines for referral in your country? Yes ❑ No ❑.
Do you use them? Yes ❑ No ❑
3.2.2 Lack of knowledge of the patient condition ❑
3.2.3 Partial response to the first line treatment ❑
3.2.4 Need of differential diagnosis ❑
3.2.5 Diagnostic uncertainty ❑
3.2.6 Need of Hospital assessment (anaphylaxis, venom allergy, etc). ❑
3.2.7 Others

3.2.8 Are you aware of the EAACI competencies document for allied health professionals for allergy? Yes ❑ No ❑

3.3. Do you have access to allergy investigations in your Primary Care facility?
Yes ❑ No ❑

3.4 I have access in my Primary Care to the following investigations and I perform and I have the ability to interpret them (mark the box if you have the ability to interpret the investigation)

	Yes	No	Ability to interpret
Allergy Skin Prick Tests	❑	❑	❑
Serum Specific IgE	❑	❑	❑
Patch Tests	❑	❑	❑
Spirometry	❑	❑	❑
FeNO	❑	❑	❑

3.6 What influences your decision NOT to refer a patient to an allergist (more than one option possible)?
3.6.1 There are no allergists in my Area/Health System. ❑
3.6.2 I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed) ❑
Deleted.3.6.5 Long waiting times ❑
3.6.6 Others

Section 4

4.1 Practice of allergen immunotherapy in your country, either in the same practice or by referring to specialist service. Do you have access to immunotherapy Yes ❑ No ❑

Section 5 - Preferred Methods of Learning and Assessment

5.1 I prefer: Traditional Learning and Assessment ❑ e-Lerning and on-line assessment ❑

5.2 E-Learning Platforms. Please rank the following in their appropriateness to you. If a method is unacceptable to you, please use N/A option. (Least appropriate 1 2 3 4 5 most appropriate)

	1	2	3	4	5	N/A
Smart-Phone	❑	❑	❑	❑	❑	❑
Tablet	❑	❑	❑	❑	❑	❑
Computer	❑	❑	❑	❑	❑	❑

Section 6 - Comments

Please feel free to make any additional comments (maximum 100 words)

EAACI 2020 free fee: include your email in the case you would like participate.

A survey on allergy diagnosis and treatment in Primary Care proposed by EAACI Primary Care Working Group

Total Sample Index

1. Total sample demographic parameters
2. Self perceived education, learning and assessment preferences in the total sample
Are you aware of the GP guidelines which include guidelines for referral in your country?
Are you aware of the EAACI competencies document for allied health professionals for allergy?
Allergy teaching as undergraduate (theoretical and practical contents)
Allergy teaching as postgraduate (theoretical and practical contents)
Neither

3. Self-perceived reasons for referring patients of responders is represented in the total sample
Lack of knowledge of the patient's condition
Partial response to the first line treatment
Need of differential diagnosis
Diagnostic uncertainty
Need of hospital assessment (immunotherapy, anaphylaxis, venom allergy, etc.)

4. Self-perceived barriers to referral of responders is represented in the total sample
I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed)
There are too long waiting times

5. Self perceived access to service delivery in the total sample
Do you have access to immunotherapy in your practice or by referring to a specialised service?
Do you have access to allergy investigations in your Primary Care facility?
There are no allergists in my Area/Health System

Total sample frequencies

		Age	Gender	Primary qualifications	Area of practice	Inthecaseofbeinga GPwithspecialistin terestinallergyhow manyhoursaw
N	Valid	689	689	687	689	454
	Missing	0	0	2	0	235

		Your practice is within: (main employer)	How many patients per week come to see you whose MAIN complaint is an allergic problem?	By your estimation, what percentage of patients with allergy have visited the pharmacy exclusively prior visiting you at your Primary Care facility in a year?	Allergy teaching as undergraduate (theoretical and practical contents)	Allergy teaching as post-graduate (theoretical and practical contents)
N	Valid	622	620	621	331	331
	Missing	67	69	68	358	358

		Non of them	Lack of knowledge of the patient's condition	Partial response to the first line treatment	Need of differential diagnosis	Diagnostic uncertainty
N	Valid	127	162	280	243	340
	Missing	562	527	409	446	349

		Need of hospital assessment (anaphylaxis, venom allergy, etc.)	Are you aware of the GP guidelines which include guidelines for referral in your country?	Do you use these guidelines?	Are you aware of the EAACI competencies document for allied health professionals for allergy?	Do you have access to allergy investigations in your Primary Care facility?
N	Valid	374	491	253	515	422
	Missing	315	198	436	174	267

		Therearenoallergistsinmy Area HealthSystem	I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed)	There are too long waiting times	Do you have access to immu0therapy in your practice or by referring to a specialised service?	Which one of the following learning and assessment methods do you prefer?
N	Valid	64	354	121	516	514
	Missing	625	335	568	173	175

		Smartphone	Tablet	Computer
N	Valid	515	488	498
	Missing	174	201	191

Total Sample Demographic Parameters Frequency Table

Age

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	18 - 24	3	0.4	0.4	0.4
	25 - 34	127	18.4	18.4	18.9
	35 - 44	187	27.1	27.1	46.0
	45 - 54	189	27.4	27.4	73.4
	55 - 64	151	21.9	21.9	95.4
	65+	32	4.6	4.6	100.0
	Total	689	100.0	100.0	

Gender

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	Female	483	70.1	70.1	70.1
	Male	206	29.9	29.9	100.0
	Total	689	100.0	100.0	

Primary qualifications

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	Medical doctor	565	82.0	82.2	82.2
	Nursing	56	8.1	8.2	90.4
	Pharmacy degree/doctora	4	0.6	0.6	91.0
	Other (please	62	9.0	9.0	100.0
	Total	687	99.7	100.0	
Missing	System	2	0.3		
Total		689	100.0		

Area of practice

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	Primary Care	468	67.9	67.9	67.9
	Primary Care Clinician with	34	4.9	4.9	72.9
	General Medical	31	4.5	4.5	77.4
	Pediatrician	34	4.9	4.9	82.3
	Pediatric	3	0.4	0.4	82.7
	General Nurse	6	0.9	0.9	83.6
	Primary Care	16	2.3	2.3	85.9
	Allergy	11	1.6	1.6	87.5
	Dietician	28	4.1	4.1	91.6
	Pharmacist	2	0.3	0.3	91.9
	Other	56	8.1	8.1	100.0
	Total	689	100.0	100.0	

In the case of being a GP with specialist interest in allergy how many hours a week do you work in this?

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	I am not a GP with specialist interest in	299	43.4	65.9	65.9
	0 - 8 hours	121	17.6	26.7	92.5
	8 - 16 hours	13	1.9	2.9	95.4
	16 - 24 hours	12	1.7	2.6	98.0
	24 - 32 hours	6	0.9	1.3	99.3
	32 - 40 hours	3	0.4	0.7	100.0
	Total	454	65.9	100.0	
Missing	System	235	34.1		
Total		689	100.0		

Your practice is within: (main employer)

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	Contracted to state or	470	68.2	75.6	75.6
	Private	77	11.2	12.4	87.9
	University, college or	14	2.0	2.3	90.2
	Retired, not currently	2	0.3	0.3	90.5
	Other	59	8.6	9.5	100.0
	Total	622	90.3	100.0	
Missing	System	67	9.7		
Total		689	100.0		

How many patients per week come to see you whose MAIN complaint is an allergic problem?

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	0 - 10	446	64.7	71.9	71.9
	11 - 25	138	20.0	22.3	94.2
	26 - 50	24	3.5	3.9	98.1
	50 - 100	8	1.2	1.3	99.4
	> 100	4	0.6	0.6	100.0
	Total	620	90.0	100.0	
Missing	System	69	10.0		
Total		689	100.0		

By your estimation, what percentage of patients with allergy have visited the pharmacy exclusively prior visiting you at your Primary Care facility in a year?

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	0 - 10 %	188	27.3	30.3	30.3
	11 - 25 %	155	22.5	25.0	55.2
	26 - 50 %	141	20.5	22.7	77.9
	50 - 100 %	56	8.1	9.0	87.0
	I don't know	81	11.8	13.0	100.0
	Total	621	90.1	100.0	
Missing	System	68	9.9		
Total		689	100.0		

Allergy teaching as undergraduate (theoretical and practical contents)

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	Allergy teaching as undergraduate (theoretical and practical	331	48.0	100.0	100.0
Missing	System	358	52.0		
Total		689	100.0		

Allergy teaching as post-graduate (theoretical and practical contents)

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	Allergy teaching as post-graduate (theoretical	331	48.0	100.0	100.0
Missing	System	358	52.0		
Total		689	100.0		

Non of them

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	None of them	127	18.4	100.0	100.0
Missing	System	562	81.6		

Total		689	100.0		

Lack of knowledge of the patient's condition

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	Lack of knowledge of	162	23.5	100.0	100.0
Missing	System	527	76.5		
Total		689	100.0		

Partial response to the first line treatment

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	Partial response to	280	40.6	100.0	100.0
Missing	System	409	59.4		
Total		689	100.0		

Need of differential diagnosis

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	Need of differential	243	35.3	100.0	100.0
Missing	System	446	64.7		
Total		689	100.0		

Diagnostic uncertainty

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	Diagnostic	340	49.3	100.0	100.0
Missing	System	349	50.7		
Total		689	100.0		

Need of hospital assessment (anaphylaxis, venom allergy, etc.)

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	Need of hospital assessment (anaphylaxis,	374	54.3	100.0	100.0
Missing	System	315	45.7		
Total		689	100.0		

Are you aware of the GP guidelines which include guidelines for referral in your country?

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	No	242	35.1	49.3	49.3
	Yes	249	36.1	50.7	100.0

	Total	491	71.3	100.0	
Missing	System	198	28.7		
Total		689	100.0		

Do you use these guidelines?

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	No	58	8.4	22.9	22.9
	Yes	195	28.3	77.1	100.0
	Total	253	36.7	100.0	
Missing	System	436	63.3		
Total		689	100.0		

Are you aware of the EAACI competencies document for allied health professionals for allergy?

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	No	453	65.7	88.0	88.0
	Yes	62	9.0	12.0	100.0
	Total	515	74.7	100.0	
Missing	System	174	25.3		
Total		689	100.0		

Do you have access to allergy investigations in your Primary Care facility?

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	No	244	35.4	57.8	57.8
	Yes	178	25.8	42.2	100.0
	Total	422	61.2	100.0	
Missing	System	267	38.8		
Total		689	100.0		

There are no allergists in my Area/HealthSystem

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	There are no in my	64	9.3	100.0	100.0
Missing	System	625	90.7		
Total		689	100.0		

I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed)

	Frequency	Percentage	Valid percentage	Cumulative percentage

Valid	I consider that the patient's condition could be diagnosed and treated in this PC facility	354	51.4	100.0	100.0
Missing	System	335	48.6		
Total		689	100.0		

There are too long waiting times

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	There are too long waiting	121	17.6	100.0	100.0
Missing	System	568	82.4		
Total		689	100.0		

Do you have access to immuotherapy in your practice or by referring to a specialised service?

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	No	257	37.3	49.8	49.8
	Yes	259	37.6	50.2	100.0
	Total	516	74.9	100.0	
Missing	System	173	25.1		
Total		689	100.0		

Which one of the following learning and assessment methods do you prefer?

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	Traditional Learning and	284	41.2	55.3	55.3
	E-Learning and on-line	230	33.4	44.7	100.0
	Total	514	74.6	100.0	
Missing	System	175	25.4		
Total		689	100.0		

Smartphone

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	N/A	23	3.3	4.5	4.5
	1	74	10.7	14.4	18.8
	2	73	10.6	14.2	33.0
	3	99	14.4	19.2	52.2
	4	116	16.8	22.5	74.8
	5	130	18.9	25.2	100.0
	Total	515	74.7	100.0	
Missing	System	174	25.3		
Total		689	100.0		

Tablet

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	N/A	31	4.5	6.4	6.4
	1	52	7.5	10.7	17.0
	2	37	5.4	7.6	24.6
	3	94	13.6	19.3	43.9
	4	137	19.9	28.1	71.9
	5	137	19.9	28.1	100.0
	Total	488	70.8	100.0	
Missing	System	201	29.2		
Total		689	100.0		

Computer

		Frequency	Percentage	Valid percentage	Cumulative percentage
Valid	N/A	9	1.3	1.8	1.8
	1	11	1.6	2.2	4.0
	2	20	2.9	4.0	8.0
	3	59	8.6	11.8	19.9
	4	139	20.2	27.9	47.8
	5	260	37.7	52.2	100.0
	Total	498	72.3	100.0	
Missing	System	191	27.7		
Total		689	100.0		

Index

United Kingdom

1. Demographic parameters
2. Self perceived education, learning and assessment preferences by country
   - Are you aware of the GP guidelines which include guidelines for referral in your country?
   - Are you aware of the EAACI competencies document for allied health professionals for allergy?
   - Allergy teaching as undergraduate (theoretical and practical contents)
   - Allergy teaching as postgraduate (theoretical and practical contents)
   - Neither
3. Self-perceived reasons for referring patients of responders is represented in the total sample
   - Lack of knowledge of the patient's condition
   - Partial response to the first line treatment
   - Need of differential diagnosis
   - Diagnostic uncertainty
   - Need of hospital assessment (immunotherapy, anaphylaxis, venom allergy, etc.)
4. Self-perceived barriers to referral of responders is represented in the total sample
   - I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed)
   - There are too long waiting times
5. Self perceived access to service delivery in the total sample
   - Do you have access to immunotherapy in your practice or by referring to a specialised service?
   - Do you have access to allergy investigations in your Primary Care facility?
   - There are no allergists in my Area/Health System

Spain

1. Demographic parameters
2. Self perceived education, learning and assessment preferences by country
   - Are you aware of the GP guidelines which include guidelines for referral in your country?
   - Are you aware of the EAACI competencies document for allied health professionals for allergy?
   - Allergy teaching as undergraduate (theoretical and practical contents)
   - Allergy teaching as postgraduate (theoretical and practical contents)
   - Neither
3. Self-perceived reasons for referring patients of responders is represented in the total sample
   - Lack of knowledge of the patient's condition
   - Partial response to the first line treatment

	Need of differential diagnosis
	Diagnostic uncertainty
	Need of hospital assessment (immunotherapy, anaphylaxis, venom allergy, etc.)
	4. Self-perceived barriers to referral of responders is represented in the total sample
	I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed)
	There are too long waiting times
	5. Self perceived access to service delivery in the total sample
	Do you have access to immunotherapy in your practice or by referring to a specialised service?
	Do you have access to allergy investigations in your Primary Care facility?
	There are no allergists in my Area/Health System
The Netherland	1. Demographic parameters
	2. Self perceived education, learning and assessment preferences by country
	Are you aware of the GP guidelines which include guidelines for referral in your country?
	Are you aware of the EAACI competencies document for allied health professionals for allergy?
	Allergy teaching as undergraduate (theoretical and practical contents)
	Allergy teaching as postgraduate (theoretical and practical contents)
	Neither
	3. Self-perceived reasons for referring patients of responders is represented in the total sample
	Lack of knowledge of the patient's condition
	Partial response to the first line treatment
	Need of differential diagnosis
	Diagnostic uncertainty
	Need of hospital assessment (immunotherapy, anaphylaxis, venom allergy, etc.)
	4. Self-perceived barriers to referral of responders is represented in the total sample
	I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed)
	There are too long waiting times
	5. Self perceived access to service delivery in the total sample
	Do you have access to immunotherapy in your practice or by referring to a specialised service?
	Do you have access to allergy investigations in your Primary Care facility?
	There are no allergists in my Area/Health System
Poland	1. Demographic parameters

	2. Self perceived education, learning and assessment preferences by country
	Are you aware of the GP guidelines which include guidelines for referral in your country?
	Are you aware of the EAACI competencies document for allied health professionals for allergy?
	Allergy teaching as undergraduate (theoretical and practical contents)
	Allergy teaching as postgraduate (theoretical and practical contents)
	Neither
	3. Self-perceived reasons for referring patients of responders is represented in the total sample
	Lack of knowledge of the patient's condition
	Partial response to the first line treatment
	Need of differential diagnosis
	Diagnostic uncertainty
	Need of hospital assessment (immunotherapy, anaphylaxis, venom allergy, etc.)
	4. Self-perceived barriers to referral of responders is represented in the total sample
	I consider that the patient’s condition could be diagnosed and treated in this PC facility (properly addressed)
	There are too long waiting times
	5. Self perceived access to service delivery in the total sample
	Do you have access to immunotherapy in your practice or by referring to a specialised service?
	Do you have access to allergy investigations in your Primary Care facility?
	There are no allergists in my Area/Health System
Italy	1. Demographic parameters
	2. Self perceived education, learning and assessment preferences by country
	Are you aware of the GP guidelines which include guidelines for referral in your country?
	Are you aware of the EAACI competencies document for allied health professionals for allergy?
	Allergy teaching as undergraduate (theoretical and practical contents)
	Allergy teaching as postgraduate (theoretical and practical contents)
	Neither
	3. Self-perceived reasons for referring patients of responders is represented in the total sample
	Lack of knowledge of the patient's condition
	Partial response to the first line treatment
	Need of differential diagnosis
	Diagnostic uncertainty
	Need of hospital assessment (immunotherapy, anaphylaxis, venom allergy, etc.)

4. Self-perceived barriers to referral of responders is represented in the total sample

I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed)

There are too long waiting times

5. Self perceived access to service delivery in the total sample

Do you have access to immunotherapy in your practice or by referring to a specialised service?

Do you have access to allergy investigations in your Primary Care facility?

There are no allergists in my Area/Health System

Frequencies

Country = United Kingdom

Demographic parameters frequency table

Age[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	18 - 24	1	0.3	0.3	0.3
	25 - 34	45	12.9	12.9	13.2
	35 - 44	119	34.2	34.2	47.4
	45 - 54	104	29.9	29.9	77.3
	55 - 64	69	19.8	19.8	97.1
	65+	10	2.9	2.9	100.0
	Total	348	100.0	100.0	

a. Country = United Kingdom

Gender[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Female	267	76.7	76.7	76.7
	Male	81	23.3	23.3	100.0
	Total	348	100.0	100.0	

a. Country = United Kingdom

Area of practice[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Primary Care Clinician	194	55.7	55.7	55.7
	Primary Care Clinician with an interest in allergy	19	5.5	5.5	61.2
	General Medical Specialist	10	2.9	2.9	64.1
	Pediatrician	18	5.2	5.2	69.3
	Pediatric Allergist	3	0.9	0.9	70.1
	General Nurse	5	1.4	1.4	71.6
	Primary Care Nurse	16	4.6	4.6	76.1
	Allergy Specialist Nurse	11	3.2	3.2	79.3
	Dietician	27	7.8	7.8	87.1
	Pharmacist	2	0.6	0.6	87.6
	Other	43	12.4	12.4	100.0
	Total	348	100.0	100.0	

a. Country = United Kingdom

In the case of being a GP with specialist interest in allergy how many hours a week do you work in this a

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I am not a GP with specialist interest in allergy	227	65.2	83.8	83.8
	0 - 8 hours	28	8.0	10.3	94.1
	8 - 16 hours	4	1.1	1.5	95.6
	16 - 24 hours	6	1.7	2.2	97.8
	24 - 32 hours	4	1.1	1.5	99.3
	32 - 40 hours	2	0.6	0.7	100.0
	Total	271	77.9	100.0	
Missing	Data	77	22.1		
Total		348	100.0		

a. Country = United Kingdom

Your practice is within: (main employer)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Contracted to state or district health Service	232	66.7	75.8	75.8
	Private practice	30	8.6	9.8	85.6
	University, college or equivalent	12	3.4	3.9	89.5
	Retired, not currently working	1	0.3	0.3	89.9
	Other	31	8.9	10.1	100.0
	Total	306	87.9	100.0	
Missing	Data	42	12.1		
Total		348	100.0		

a. Country = United Kingdom

How many patients per week come to see you whose MAIN complaint is an allergic problem?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	0 - 10	234	67.2	76.5	76.5
	11 - 25	52	14.9	17.0	93.5
	26 - 50	13	3.7	4.2	97.7
	50 - 100	4	1.1	1.3	99.0
	> 100	3	0.9	1.0	100.0
	Total	306	87.9	100.0	
Missing	Data	42	12.1		
Total		348	100.0		

a. Country = United Kingdom

By your estimation, what percentage of patients with allergy have visited the pharmacy exclusively prior visiting you at your Primary Care facility in a year?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	0 - 10 %	89	25.6	29.1	29.1
	11 - 25 %	73	21.0	23.9	52.9
	26 - 50 %	65	18.7	21.2	74.2
	50 - 100 %	25	7.2	8.2	82.4
	I don't know	54	15.5	17.6	100.0
	Total	306	87.9	100.0	
Missing	Data	42	12.1		
Total		348	100.0		

a. Country = United Kingdom

Allergy teaching as undergraduate (theoretical and practical contents)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Allergy teaching as undergraduate (theoretical and practical contents)	160	46.0	100.0	100.0
Missing	Data	188	54.0		
Total		348	100.0		

a. Country = United Kingdom

Allergy teaching as post-graduate (theoretical and practical contents)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Allergy teaching as post-graduate (theoretical and practical contents)	157	45.1	100.0	100.0
Missing	Data	191	54.9		
Total		348	100.0		

a. Country = United Kingdom

Non of them[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	None of them	73	21.0	100.0	100.0
Missing	Data	275	79.0		
Total		348	100.0		

a. Country = United Kingdom

Anaphylaxis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	12	3.4	4.6	4.6
	1	4	1.1	1.5	6.2
	2	7	2.0	2.7	8.8
	3	23	6.6	8.8	17.7
	4	89	25.6	34.2	51.9
	5	125	35.9	48.1	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Rhinitis / asthma[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	10	2.9	3.8	3.8
	1	3	0.9	1.2	5.0
	2	8	2.3	3.1	8.1
	3	29	8.3	11.2	19.2
	4	112	32.2	43.1	62.3
	5	98	28.2	37.7	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Atopic dermatitis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	11	3.2	4.2	4.2
	1	9	2.6	3.5	7.7
	2	17	4.9	6.5	14.2
	3	46	13.2	17.7	31.9
	4	99	28.4	38.1	70.0
	5	78	22.4	30.0	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Contact dermatitis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	14	4.0	5.4	5.4
	1	10	2.9	3.8	9.2
	2	16	4.6	6.2	15.4
	3	54	15.5	20.8	36.2
	4	109	31.3	41.9	78.1
	5	57	16.4	21.9	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Urticaria and angioedema[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	7	2.0	2.7	2.7
	1	6	1.7	2.3	5.0
	2	28	8.0	10.8	15.8
	3	48	13.8	18.5	34.2
	4	93	26.7	35.8	70.0
	5	78	22.4	30.0	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Food allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	0.3	0.4	0.4
	1	19	5.5	7.3	7.7
	2	43	12.4	16.5	24.2
	3	79	22.7	30.4	54.6
	4	75	21.6	28.8	83.5
	5	43	12.4	16.5	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Drug allergy (immediate and delayed)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	13	3.7	5.0	5.0
	1	12	3.4	4.6	9.6
	2	50	14.4	19.2	28.8
	3	77	22.1	29.6	58.5
	4	79	22.7	30.4	88.8
	5	29	8.3	11.2	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Venom allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	70	20.1	26.9	26.9
	1	63	18.1	24.2	51.2
	2	37	10.6	14.2	65.4
	3	39	11.2	15.0	80.4
	4	31	8.9	11.9	92.3
	5	20	5.7	7.7	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Occupational allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	26	7.5	10.0	10.0
	1	26	7.5	10.0	20.0
	2	60	17.2	23.1	43.1
	3	92	26.4	35.4	78.5
	4	46	13.2	17.7	96.2
	5	10	2.9	3.8	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Latex allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	26	7.5	10.0	10.0
	1	23	6.6	8.8	18.8
	2	53	15.2	20.4	39.2
	3	85	24.4	32.7	71.9
	4	48	13.8	18.5	90.4
	5	25	7.2	9.6	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Understanding of terms like sensitisation, atopy, type I and type IV allergya

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	7	2.0	2.7	2.7
	1	25	7.2	9.6	12.3
	2	45	12.9	17.3	29.6
	3	75	21.6	28.8	58.5
	4	59	17.0	22.7	81.2
	5	49	14.1	18.8	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Understanding of cross-reactivity[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	7	2.0	2.7	2.7
	1	37	10.6	14.2	16.9
	2	56	16.1	21.5	38.5
	3	59	17.0	22.7	61.2
	4	73	21.0	28.1	89.2
	5	28	8.0	10.8	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Basic mechanisms of allergic/non-allergic rhinitis and organic disorders (for example in the nose and sinus)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	10	2.9	3.8	3.8
	1	19	5.5	7.3	11.2
	2	39	11.2	15.0	26.2
	3	73	21.0	28.1	54.2
	4	83	23.9	31.9	86.2
	5	36	10.3	13.8	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Pharmacologic therapy (basic mechanisms of common drugs for inflammatory disorders in airways and skin)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	12	3.4	4.6	4.6
	1	19	5.5	7.3	11.9
	2	34	9.8	13.1	25.0
	3	58	16.7	22.3	47.3
	4	104	29.9	40.0	87.3
	5	33	9.5	12.7	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Immunotherapy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	23	6.6	8.8	8.8
	1	64	18.4	24.6	33.5
	2	80	23.0	30.8	64.2
	3	51	14.7	19.6	83.8
	4	28	8.0	10.8	94.6
	5	14	4.0	5.4	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		

Total		348	100.0		

a. Country = United Kingdom

Environmental Control Measures[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	19	5.5	7.3	7.3
	1	30	8.6	11.5	18.8
	2	62	17.8	23.8	42.7
	3	65	18.7	25.0	67.7
	4	61	17.5	23.5	91.2
	5	23	6.6	8.8	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Risk assessment for anaphylaxis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	6	1.7	2.3	2.3
	1	16	4.6	6.2	8.5
	2	44	12.6	16.9	25.4
	3	80	23.0	30.8	56.2
	4	70	20.1	26.9	83.1
	5	44	12.6	16.9	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Prescription/training of adrenaline[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	11	3.2	4.2	4.2
	1	28	8.0	10.8	15.0
	2	36	10.3	13.8	28.8
	3	57	16.4	21.9	50.8
	4	74	21.3	28.5	79.2
	5	54	15.5	20.8	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		

Total		348	100.0		

a. Country = United Kingdom

Identifying patients who need to be referred to an allergista

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	5	1.4	1.9	1.9
	1	11	3.2	4.2	6.2
	2	27	7.8	10.4	16.5
	3	71	20.4	27.3	43.8
	4	92	26.4	35.4	79.2
	5	54	15.5	20.8	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Lack of knowledge of the patient's condition[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Lack of knowledge of the patient's condition	112	32.2	100.0	100.0
Missing	Data	236	67.8		
Total		348	100.0		

a. Country = United Kingdom

Partial response to the first line treatment[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Partial response to the first line treatment	126	36.2	100.0	100.0
Missing	Data	222	63.8		
Total		348	100.0		

a. Country = United Kingdom

Need of differential diagnosis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Need of differential diagnosis	104	29.9	100.0	100.0
Missing	Data	244	70.1		
Total		348	100.0		

a. Country = United Kingdom

Diagnostic uncertainty[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Diagnostic uncertainty	195	56.0	100.0	100.0
Missing	Data	153	44.0		
Total		348	100.0		

a. Country = United Kingdom

Need of hospital assessment (anaphylaxis, venom allergy, etc.)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Need of hospital assessment (anaphylaxis, venom allergy, etc.)	195	56.0	100.0	100.0
Missing	Data	153	44.0		
Total		348	100.0		

a. Country = United Kingdom

Other (please specify)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		314	90.2	90.2	90.2
	availability of some one to refer to	1	0.3	0.3	90.5
	carrying out specific tests	1	0.3	0.3	90.8
	complex patient story	1	0.3	0.3	91.1
	degree of symptoms and where avoidance of assumed allergen has not assuaged symptoms	1	0.3	0.3	91.4
	don't see patients	1	0.3	0.3	91.7
	Food challenges	1	0.3	0.3	92.0
	Gp would need to refer	1	0.3	0.3	92.2
	Guidelines advise	1	0.3	0.3	92.5
	i am a practice nurse and a school nurse so i dont make the referral	1	0.3	0.3	92.8
	I am the specialist allergist	1	0.3	0.3	93.1
	I don't diagnose and refer	1	0.3	0.3	93.4

If they require secondary or tertiary input e.g. persistant blood/mucus in stool, persistant poor weight gain, multiple IgE allergy, requires NGT due to feeding aversion	1	0.3	0.3	93.7
immunotherapy	1	0.3	0.3	94.0
Immunotherapy	1	0.3	0.3	94.3
knowledge of long waiting list	1	0.3	0.3	94.5
Lack of specilists / very long waiting time	1	0.3	0.3	94.8
need for IT assessment, food challerngr or drug allergy investigsation	1	0.3	0.3	95.1
need for skin prick testing not available in primary care	1	0.3	0.3	95.4
Need for SPT to guide management e.g. hospital vs home challenges/weaning advice.	1	0.3	0.3	95.7
Not applicable in current role	1	0.3	0.3	96.0
Patchtesting/skin prick testing	1	0.3	0.3	96.3
Patient advice regarding management especially children and reintroducing foods eg milk or egg	1	0.3	0.3	96.6
patient demand	1	0.3	0.3	96.8
Patient influence	1	0.3	0.3	97.1
Patient pressure	2	0.6	0.6	97.7
Poor response to all options of treatment in primary care	1	0.3	0.3	98.0
pressure from patient as I come across as uncertain and so they lack confidence in me	1	0.3	0.3	98.3
severe allergy requiring epipen as i think this is part of NICE	1	0.3	0.3	98.6
shared management plan - patients and GP's are v frightened of allergy	1	0.3	0.3	98.9

	SPT and/or specific IgE +/- OPEN FOOD CHALLENGES	1	0.3	0.3	99.1
	Tests to confirm or exclude allergy, to exclude allergy as cause of uncertain symptoms	1	0.3	0.3	99.4
	Time to take an accurate allergy history	1	0.3	0.3	99.7
	To arrange allergy tests	1	0.3	0.3	100.0
	Total	348	100.0	100.0	

a. Country = United Kingdom

Are you aware of the GP guidelines which include guidelines for referral in your country?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	141	40.5	54.2	54.2
	Yes	119	34.2	45.8	100.0
	Total	260	74.7	100.0	
Missing	Data	88	25.3		
Total		348	100.0		

a. Country = United Kingdom

Do you use these guidelines?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	32	9.2	27.1	27.1
	Yes	86	24.7	72.9	100.0
	Total	118	33.9	100.0	
Missing	Data	230	66.1		
Total		348	100.0		

a. Country = United Kingdom

Are you aware of the EAACI competencies document for allied health professionals for allergy?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	210	60.3	82.0	82.0
	Yes	46	13.2	18.0	100.0
	Total	256	73.6	100.0	
Missing	Data	92	26.4		
Total		348	100.0		

a. Country = United Kingdom

Do you have access to allergy investigations in your Primary Care facility?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	130	37.4	50.8	50.8
	Yes	126	36.2	49.2	100.0
	Total	256	73.6	100.0	
Missing	Data	92	26.4		
Total		348	100.0		

a. Country = United Kingdom

AllergySkinPrickTests[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	88	25.3	71.0	71.0
	Yes	36	10.3	29.0	100.0
	Total	124	35.6	100.0	
Missing	Data	224	64.4		
Total		348	100.0		

a. Country = United Kingdom

Serum Specific IgE[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	14	4.0	11.3	11.3
	Yes	110	31.6	88.7	100.0
	Total	124	35.6	100.0	
Missing	Data	224	64.4		
Total		348	100.0		

a. Country = United Kingdom

Patch Tests[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	108	31.0	87.1	87.1
	Yes	16	4.6	12.9	100.0
	Total	124	35.6	100.0	
Missing	Data	224	64.4		
Total		348	100.0		

a. Country = United Kingdom

Spirometry[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage

Valid	No	14	4.0	11.3	11.3
	Yes	110	31.6	88.7	100.0
	Total	124	35.6	100.0	
Missing	Data	224	64.4		
Total		348	100.0		

a. Country = United Kingdom

FENOa

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	111	31.9	89.5	89.5
	Yes	13	3.7	10.5	100.0
	Total	124	35.6	100.0	
Missing	Data	224	64.4		
Total		348	100.0		

a. Country = United Kingdom

Allergy Skin Prick Tests a

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	72	20.7	58.1	58.1
	Yes	52	14.9	41.9	100.0
	Total	124	35.6	100.0	
Missing	Data	224	64.4		
Total		348	100.0		

a. Country = United Kingdom

Serum Specific IgE[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	25	7.2	20.2	20.2
	Yes	99	28.4	79.8	100.0
	Total	124	35.6	100.0	
Missing	Data	224	64.4		
Total		348	100.0		

a. Country = United Kingdom

Patch Tests[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	104	29.9	83.9	83.9
	Yes	20	5.7	16.1	100.0
	Total	124	35.6	100.0	
Missing	Data	224	64.4		

Total		348	100.0		

a. Country = United Kingdom

FENOa

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	103	29.6	83.1	83.1
	Yes	21	6.0	16.9	100.0
	Total	124	35.6	100.0	
Missing	Data	224	64.4		
Total		348	100.0		

a. Country = United Kingdom

There are no allergists in my Area/Health System a

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	There are no in my Area/Health System	37	10.6	100.0	100.0
Missing	Data	311	89.4		
Total		348	100.0		

a. Country = United Kingdom

I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed)	183	52.6	100.0	100.0
Missing	Data	165	47.4		
Total		348	100.0		

a. Country = United Kingdom

There are too long waiting times[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	There are too long waiting times	55	15.8	100.0	100.0
Missing	Data	293	84.2		
Total		348	100.0		

a. Country = United Kingdom

Other (please specify)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		314	90.2	90.2	90.2
	allergy condition ruled out	1	0.3	0.3	90.5
	always refer if they have allergic presentation	1	0.3	0.3	90.8
	As a health visitor I would refer to the GP	1	0.3	0.3	91.1
	as prev statd i do not make these referrals in my nursing capcidy	1	0.3	0.3	91.4
	do not know enough about	1	0.3	0.3	91.7
	don't see patients	1	0.3	0.3	92.0
	Gp needs to do referral	1	0.3	0.3	92.2
	I am a secondary care paediatrician with interest in allergy	1	0.3	0.3	92.5
	I am an emergency GP	1	0.3	0.3	92.8
	I don't have the option to directly refer to allergist.	1	0.3	0.3	93.1
	I don't refer	2	0.6	0.6	93.7
	I don’t refer	1	0.3	0.3	94.0
	I generally refer if I think the patient needs it or I need a second d opinion. The existence of wait lists is neither here nor there.	1	0.3	0.3	94.3
	I refer	1	0.3	0.3	94.5
	If it is simple allergy eg hayfever and not having significant impact on life	1	0.3	0.3	94.8
	If primary suspicion is not an allergy	1	0.3	0.3	95.1
	Locum - unable to follow up referral.	1	0.3	0.3	95.4
	n/a	1	0.3	0.3	95.7
	N/A always refer if patient preference, need for épipen or in young children	1	0.3	0.3	96.0
	None	1	0.3	0.3	96.3
	Not applicable	1	0.3	0.3	96.6
	Not feeling confident regarding the referral criteria	1	0.3	0.3	96.8
	not working in primary care	1	0.3	0.3	97.1

	Only see patients once they have been seen by a paediatric consutltant	1	0.3	0.3	97.4
	Patient influence	1	0.3	0.3	97.7
	People are referred to consultant opinion	1	0.3	0.3	98.0
	really only available for patients with anaphylaxis in this area	1	0.3	0.3	98.3
	Referral done only in treatment resistant cases	1	0.3	0.3	98.6
	We have an in house Paediatric allergy service but not adult	1	0.3	0.3	98.9
	We run a hospital based clinic accepting GP referrals and can access advice from our Consultant Allergist colleagues as required	1	0.3	0.3	99.1
	What is an allergist? What do they do?	1	0.3	0.3	99.4
	work in a consultant clinic with specialist interest	1	0.3	0.3	99.7
	Would advise to see their GP	1	0.3	0.3	100.0
	Total	348	100.0	100.0	

a. Country = United Kingdom

Do you have access to immuotherapy in your practice or by referring to a specialised service?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	124	35.6	49.8	49.8
	Yes	125	35.9	50.2	100.0
	Total	249	71.6	100.0	
Missing	Data	99	28.4		
Total		348	100.0		

a. Country = United Kingdom

Which one of the following learning and assessment methods do you prefer?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Traditional Learning and Assessment	123	35.3	49.6	49.6
	E-Learning and on-line assessment	125	35.9	50.4	100.0
	Total	248	71.3	100.0	

Missing	Data	100	28.7		
Total		348	100.0		

a. Country = United Kingdom

Smartphone[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	N/A	15	4.3	6.0	6.0
	1	37	10.6	14.9	21.0
	2	33	9.5	13.3	34.3
	3	53	15.2	21.4	55.6
	4	52	14.9	21.0	76.6
	5	58	16.7	23.4	100.0
	Total	248	71.3	100.0	
Missing	Data	100	28.7		
Total		348	100.0		

a. Country = United Kingdom

Tablet[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	N/A	21	6.0	8.5	8.5
	1	10	2.9	4.0	12.5
	2	22	6.3	8.9	21.4
	3	50	14.4	20.2	41.5
	4	64	18.4	25.8	67.3
	5	81	23.3	32.7	100.0
	Total	248	71.3	100.0	
Missing	Data	100	28.7		
Total		348	100.0		

a. Country = United Kingdom

Computer[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	N/A	3	0.9	1.2	1.2
	1	3	0.9	1.2	2.4
	2	8	2.3	3.2	5.6
	3	34	9.8	13.7	19.4
	4	64	18.4	25.8	45.2
	5	136	39.1	54.8	100.0
	Total	248	71.3	100.0	
Missing	Data	100	28.7		
Total		348	100.0		

a. Country = United Kingdom

Open-Ended Response[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		292	83.9	83.9	83.9
	-	1	0.3	0.3	84.2
	.	1	0.3	0.3	84.5
	Allegy disease is very common, and I see it very offen in my everyday practice	1	0.3	0.3	84.8
	Allergy is greatly overlooked in medical training? Yes is highly prevalent. To pursue a further interest is quite costly (personally I have found the money as it's important) but this is a potential barrier to further training. Thank you	1	0.3	0.3	85.1
	Although I placed smartphone, tablets and computer as a suitable learning platform, it is only for specific conditions such as allergic rhinitis. In my opinion, conditions like atopic dermatitis and contact dermatitis should be taught in the traditional face-to-face way, to get the most out of it	1	0.3	0.3	85.3
	As an ANP I'm very interested in increasing my knowledge especially in a urgent care unit as I have com across these Pt in the past and I am concerned that I may not have given the correct treatment. I think all of us would embrace learning	1	0.3	0.3	85.6

As primary care Paediatric Dietitian employed in a Baby Friendly Initiative accredited Infant Feeding Team, I am unable to attend any training events/access any online training supported/sponsored by industry as this breaches the WHO code on the Marketing of Breast Milk Substitutes. This also includes training offered by the British Dietetic Association due to their partnership with industry. As a result I feel isolated and am unable to access the many sponsored training opportunities a available. Therefore I would plea with any group to think about offering training events/online modules that are free from industry sponsorship.	1	0.3	0.3	85.9
Being allergic with anaphylactic reactions myself this survey is somewhat biased	1	0.3	0.3	86.2
Definitely a neglected area during undergraduate teaching	1	0.3	0.3	86.5
Diagnose and treatment of common allergies will be better if family physician will be possible to do standard Prick tests	1	0.3	0.3	86.8
FeNO is not available in UK Primary Care unless we fund it ourselves. We cannot afford to fund something that we cannot receive any remuneration and so would make a significant loss as we cannot charge patients	1	0.3	0.3	87.1
Ff	1	0.3	0.3	87.4

Have completed masters in allergy. Huge lack of training in undergraduate and postgraduate medical training	1	0.3	0.3	87.6
I am a dermatology GPSI so have increased knowledge particularly with regard to contact allergy and urticaria	1	0.3	0.3	87.9
I am a nurse and a mother of a 26 and 29 year old who have allergies. My daughter is in the process of getting immunotherapy treatment for chronic urticaria . She has had to go private as her urgent appointment to see an immunologist was for next 4 months(January). She has had to have over 40 shots of adrenalin in 3months. This service is woefully inadequate. Doctors and general nurses have very little idea of allergies, angioedema and causes and treatment. They have no comprehension of the impact this has on family lives. The stress at present is unbearable.	1	0.3	0.3	88.2
I am just about to start in primary care so may find there are more opportunities for diagnosis than I am aware of at present. Currently work in a minor injuries unit	1	0.3	0.3	88.5
I currently work for Cognita Schools working towards improved care standards in our schools which follow best practice in allergy management. We aim to increase awareness and understanding for our staff and a clear set of guidelines and policies to ensure best practice	1	0.3	0.3	88.8

I prefer interactive learning as issues arising can be immediately discussed.	1	0.3	0.3	89.1
I think it is difficult to Mx patients in primary care who do not have clear triggers for story and where allergy testing may help identify multiple allergens or exclude an allergy latex allergy.	1	0.3	0.3	89.4
I think this survey is beneficial for awareness of allegies on the primary care.	1	0.3	0.3	89.7
I work in primary and secondary care so have varied and opportunistic people attending with chronic respiratory conditions with allergy	1	0.3	0.3	89.9
I would love more guidance on whom to refer. I worked in an Immunology department before going to Medical School. I perceive an 'over-expectation' in the usefulness of allergy testing, especially in parents of children (and more so in those who have moved from London/Home Counties) .. so guidance would be most welcome.	1	0.3	0.3	90.2
I'm doing the MSc Allergy at Southampton University which is an excellent way of learning lots about allergy. Distinct lack of dietitians specialised in allergy for adults and a large need for adult allergy services throughout the UK.	1	0.3	0.3	90.5
in malta patients pay from pocket for services in private primary care. No reimbursements from government	1	0.3	0.3	90.8

In my health center I have the opportunity to refer a patent to dermatologist, pulmonogist or a rinologist who works in the same building for further diagnosis and treatment if necesary. It makes my work easier	1	0.3	0.3	91.1
In primary care we lack basic allergy testing, such as skin prick testing and patch testing. The number of referrals could be reduced if these were available. However finding training courses for these, particularly as stand alone modules are non-existent in UK.	1	0.3	0.3	91.4
Increased allergy training at undergraduate level for all medical students should be mandatory.	1	0.3	0.3	91.7
interesting	1	0.3	0.3	92.0
It would be great if we could get as much information on allergies as possible, through online lessons or courses	1	0.3	0.3	92.2
It would be great to have international guidelines developed mutually by the family physicians representatives and allergology/immunology representatives	1	0.3	0.3	92.5

Its a complex area that is poorly understood by most GPs. Its a topic that I find not very interesting and try to avoid. There are many Alternative Practitioners involved in this area and their practice tends to not be based on evidence and often is pseudoscience. As a GP these Alternative Practitioners I feel prey on patients vulnerability and often compete and decry conventional doctor prescribed medication and advice	1	0.3	0.3	92.8
Just because I have access to tests doesn't mean I know which to request or how to appropriately interpret	1	0.3	0.3	93.1
m	1	0.3	0.3	93.4
Many of these questions where not relevant to a health visitors role. However, we are often the first health professional that a worried parent may reach out to and so enhanced knowledge would be massively beneficial.	1	0.3	0.3	93.7
Most of my clinical knowledge comes from personal experience of allergies in my child.	1	0.3	0.3	94.0
N/a.	1	0.3	0.3	94.3
NIL	1	0.3	0.3	94.5
no comment	1	0.3	0.3	94.8
None	2	0.6	0.6	95.4
Patients often have expectations that they must have 'allergy testing' when often this is not necessary. More resources to signpost/reassure patients re this might be useful	1	0.3	0.3	95.7

problems with perioral allergy syndrome cross over with nut allergy - my son means I am keen to see allergy specialist again as diff managing.	1	0.3	0.3	96.0
Some of the questions are not yes or no but need further discussion	1	0.3	0.3	96.3
Specialist support and provision is falling woefully behind prevalence - for allergies (but of course not just allergies)	1	0.3	0.3	96.6
thanks to a number of tragic high profile allergy related deaths both patient and GP's are very frightened of allergy. Schools also are confused and lack confidence in managing it. There are some simple mesages that primary care can take on eg dosages of antihistamines, always encouraging patients to have 2 autoinjectors, pre referral tests (if any) . I feel lucky we have a good but under resourced specialist unit - guidance on who to refer to would help eg I refer atopic dermatitis to dermatology for patch testing but systemic symptoms to allergy clinic	1	0.3	0.3	96.8
The service we have from secondary care is inconsistent and often absent. We really have no current access to Dermatology either due to restrictions	1	0.3	0.3	97.1
There is a lack of understanding on allergy across the health professions	1	0.3	0.3	97.4

There is a lot of attention paid to anaphylaxis and angiooedema management, but not enough to moderate / mild / subtle allergy symptoms giving respiratory dermatology or GIT symptoms. many patients are now eliminating certain foods from their own diets adn their childrens diets in an effort to self manage their symptoms	1	0.3	0.3	97.7
There was an excellent allergy training day at Bournemouth hospital this year	1	0.3	0.3	98.0
This is an important area	1	0.3	0.3	98.3
this survey may have skewed results as there was no option to put 'not applicable' in some of the questions. The focus was on primary care and this is not where I am working.	1	0.3	0.3	98.6
very few allergy clinics available yet allergies more common. I had no idea you can get anaphylaxis with coeliac disease	1	0.3	0.3	98.9
Very limited allergy services in my area , have to refer out of county	1	0.3	0.3	99.1
We urgently need guidance on what level of training as GP authorises us to start primary care allergy services. I have extensive allergy training (MsC Allergy) but no advice if that authorises me to start an allergy service in primary care.	1	0.3	0.3	99.4
Would be helpful to have I am uncertain as an option for the questions	1	0.3	0.3	99.7

	Would love to do some evidence informed learning in this field particularly on when to refer and what tests needed	1	0.3	0.3	100.0
	Total	348	100.0	100.0	

a. Country = United Kingdom

AnaphylaxisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	34	9.8	13.7	13.7
	Adequate	214	61.5	86.3	100.0
	Total	248	71.3	100.0	
Missing	Data	100	28.7		
Total		348	100.0		

a. Country = United Kingdom

RhinitisasthmaBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	40	11.5	16.0	16.0
	Adequate	210	60.3	84.0	100.0
	Total	250	71.8	100.0	
Missing	Data	98	28.2		
Total		348	100.0		

a. Country = United Kingdom

AtopicdermatitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	72	20.7	28.9	28.9
	Adequate	177	50.9	71.1	100.0
	Total	249	71.6	100.0	
Missing	Data	99	28.4		
Total		348	100.0		

a. Country = United Kingdom

ContactdermatitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	80	23.0	32.5	32.5
	Adequate	166	47.7	67.5	100.0
	Total	246	70.7	100.0	

Missing	Data	102	29.3		
Total		348	100.0		

a. Country = United Kingdom

UrticariaandangioedemaBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	82	23.6	32.4	32.4
	Adequate	171	49.1	67.6	100.0
	Total	253	72.7	100.0	
Missing	Data	95	27.3		
Total		348	100.0		

a. Country = United Kingdom

FoodallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	141	40.5	54.4	54.4
	Adequate	118	33.9	45.6	100.0
	Total	259	74.4	100.0	
Missing	Data	89	25.6		
Total		348	100.0		

a. Country = United Kingdom

DrugallergyimmediateanddelayedBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	139	39.9	56.3	56.3
	Adequate	108	31.0	43.7	100.0
	Total	247	71.0	100.0	
Missing	Data	101	29.0		
Total		348	100.0		

a. Country = United Kingdom

VenomallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	139	39.9	73.2	73.2
	Adequate	51	14.7	26.8	100.0
	Total	190	54.6	100.0	
Missing	Data	158	45.4		
Total		348	100.0		

a. Country = United Kingdom

OccupationalallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	178	51.1	76.1	76.1
	Adequate	56	16.1	23.9	100.0
	Total	234	67.2	100.0	
Missing	Data	114	32.8		
Total		348	100.0		

a. Country = United Kingdom

LatexallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	161	46.3	68.8	68.8
	Adequate	73	21.0	31.2	100.0
	Total	234	67.2	100.0	
Missing	Data	114	32.8		
Total		348	100.0		

a. Country = United Kingdom

UnderstandingofthefollowingtermsBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	145	41.7	57.3	57.3
	Adequate	108	31.0	42.7	100.0
	Total	253	72.7	100.0	
Missing	Data	95	27.3		
Total		348	100.0		

a. Country = United Kingdom

UnderstandingofcrossreactivityBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	152	43.7	60.1	60.1
	Adequate	101	29.0	39.9	100.0
	Total	253	72.7	100.0	
Missing	Data	95	27.3		
Total		348	100.0		

a. Country = United Kingdom

BasicmechanismsofallergicnonallergicrhinitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	131	37.6	52.4	52.4

	Adequate	119	34.2	47.6	100.0
	Total	250	71.8	100.0	
Missing	Data	98	28.2		
Total		348	100.0		

a. Country = United Kingdom

PharmacologictherapyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	111	31.9	44.8	44.8
	Adequate	137	39.4	55.2	100.0
	Total	248	71.3	100.0	
Missing	Data	100	28.7		
Total		348	100.0		

a. Country = United Kingdom

ImmunotherapyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	195	56.0	82.3	82.3
	Adequate	42	12.1	17.7	100.0
	Total	237	68.1	100.0	
Missing	Data	111	31.9		
Total		348	100.0		

a. Country = United Kingdom

EnvironmentalControlMeasuresBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	157	45.1	65.1	65.1
	Adequate	84	24.1	34.9	100.0
	Total	241	69.3	100.0	
Missing	Data	107	30.7		
Total		348	100.0		

a. Country = United Kingdom

RiskassessmentforanaphylaxisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	140	40.2	55.1	55.1
	Adequate	114	32.8	44.9	100.0
	Total	254	73.0	100.0	
Missing	Data	94	27.0		
Total		348	100.0		

a. Country = United Kingdom

PrescriptiontrainingofadrenalineBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	121	34.8	48.6	48.6
	Adequate	128	36.8	51.4	100.0
	Total	249	71.6	100.0	
Missing	Data	99	28.4		
Total		348	100.0		

a. Country = United Kingdom

WithregardtopatientswithapossiblediagnosisofallergicBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	109	31.3	42.7	42.7
	Adequate	146	42.0	57.3	100.0
	Total	255	73.3	100.0	
Missing	Data	93	26.7		
Total		348	100.0		

a. Country = United Kingdom

Country = Spain

Demographic parameters frequency table

Age[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	18 - 24	2	1.5	1.5	1.5
	25 - 34	24	18.0	18.0	19.5
	35 - 44	32	24.1	24.1	43.6
	45 - 54	46	34.6	34.6	78.2
	55 - 64	28	21.1	21.1	99.2
	65+	1	0.8	0.8	100.0
	Total	133	100.0	100.0	

a. Country = Spain

Gender[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Female	102	76.7	76.7	76.7
	Male	31	23.3	23.3	100.0
	Total	133	100.0	100.0	

a. Country = Spain

Area of practice[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Primary Care Clinician	97	72.9	72.9	72.9
	Primary Care Clinician with an interest in	8	6.0	6.0	78.9
	General Medical Specialist	13	9.8	9.8	88.7
	Pediatrician	8	6.0	6.0	94.7
	Other	7	5.3	5.3	100.0
	Total	133	100.0	100.0	

a. Country = Spain

In the case of being a GP with specialist interest in allergy how many hours a week do you work in this a

		Frequency	Percentage
Missing	Data	133	100.0

a. Country = Spain

Your practice is within: (main employer)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Contracted to state or district health Service	117	88.0	97.5	97.5
	Private practice	3	2.3	2.5	100.0
	Total	120	90.2	100.0	
Missing	Data	13	9.8		
Total		133	100.0		

a. Country = Spain

How many patients per week come to see you whose MAIN complaint is an allergic problem?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	0 - 10	59	44.4	49.2	49.2
	11 - 25	52	39.1	43.3	92.5
	26 - 50	5	3.8	4.2	96.7
	50 - 100	3	2.3	2.5	99.2
	> 100	1	0.8	0.8	100.0
	Total	120	90.2	100.0	
Missing	Data	13	9.8		
Total		133	100.0		

a. Country = Spain

By your estimation, what percentage of patients with allergy have visited the pharmacy exclusively prior visiting you at your Primary Care facility in a year?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	0 - 10 %	42	31.6	35.0	35.0
	11 - 25 %	33	24.8	27.5	62.5
	26 - 50 %	33	24.8	27.5	90.0
	50 - 100 %	6	4.5	5.0	95.0
	I don't know	6	4.5	5.0	100.0
	Total	120	90.2	100.0	
Missing	Data	13	9.8		
Total		133	100.0		

a. Country = Spain

Allergy teaching as undergraduate (theoretical and practical contents)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Allergy teaching as undergraduate (theoretical and practical	61	45.9	100.0	100.0
Missing	Data	72	54.1		
Total		133	100.0		

a. Country = Spain

Allergy teaching as post-graduate (theoretical and practical contents)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Allergy teaching as post-graduate (theoretical	49	36.8	100.0	100.0
Missing	Data	84	63.2		
Total		133	100.0		

a. Country = Spain

Non of them[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	None of them	33	24.8	100.0	100.0
Missing	Data	100	75.2		
Total		133	100.0		

a. Country = Spain

Anaphylaxis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	3	2.3	2.8	2.8
	2	4	3.0	3.7	6.5
	3	20	15.0	18.7	25.2
	4	47	35.3	43.9	69.2
	5	33	24.8	30.8	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Rhinitis / asthma[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	0.8	0.9	0.9
	2	2	1.5	1.9	2.8
	3	11	8.3	10.3	13.1
	4	50	37.6	46.7	59.8
	5	43	32.3	40.2	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Atopic dermatitis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	0.8	0.9	0.9
	1	1	0.8	0.9	1.9
	2	6	4.5	5.6	7.5
	3	32	24.1	29.9	37.4
	4	40	30.1	37.4	74.8
	5	27	20.3	25.2	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Contact dermatitis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	1	0.8	0.9	0.9
	2	8	6.0	7.5	8.4
	3	35	26.3	32.7	41.1
	4	45	33.8	42.1	83.2
	5	18	13.5	16.8	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Urticaria and angioedema[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	2	1.5	1.9	1.9
	2	7	5.3	6.5	8.4
	3	23	17.3	21.5	29.9
	4	47	35.3	43.9	73.8
	5	28	21.1	26.2	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Food allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	3	2.3	2.8	2.8
	1	3	2.3	2.8	5.6
	2	18	13.5	16.8	22.4
	3	43	32.3	40.2	62.6
	4	36	27.1	33.6	96.3
	5	4	3.0	3.7	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Drug allergy (immediate and delayed)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	0.8	0.9	0.9
	1	2	1.5	1.9	2.8
	2	17	12.8	15.9	18.7
	3	46	34.6	43.0	61.7
	4	34	25.6	31.8	93.5
	5	7	5.3	6.5	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Venom allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	3	2.3	2.8	2.8
	1	8	6.0	7.5	10.3
	2	23	17.3	21.5	31.8
	3	39	29.3	36.4	68.2
	4	23	17.3	21.5	89.7
	5	11	8.3	10.3	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Occupational allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	8	6.0	7.5	7.5
	1	11	8.3	10.3	17.8
	2	29	21.8	27.1	44.9
	3	40	30.1	37.4	82.2
	4	17	12.8	15.9	98.1
	5	2	1.5	1.9	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Latex allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	5	3.8	4.7	4.7
	1	6	4.5	5.6	10.3
	2	22	16.5	20.6	30.8
	3	43	32.3	40.2	71.0
	4	21	15.8	19.6	90.7
	5	10	7.5	9.3	100.0

	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Understanding of terms like sensitisation, atopy, type I and type IV allergya

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	0.8	0.9	0.9
	1	2	1.5	1.9	2.8
	2	27	20.3	25.2	28.0
	3	35	26.3	32.7	60.7
	4	33	24.8	30.8	91.6
	5	9	6.8	8.4	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Understanding of cross-reactivity[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	2	1.5	1.9	1.9
	1	5	3.8	4.7	6.5
	2	24	18.0	22.4	29.0
	3	29	21.8	27.1	56.1
	4	34	25.6	31.8	87.9
	5	13	9.8	12.1	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Basic mechanisms of allergic/non-allergic rhinitis and organic disorders (for example in the nose and sinus)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	0.8	0.9	0.9
	2	18	13.5	16.8	17.8

	3	40	30.1	37.4	55.1
	4	35	26.3	32.7	87.9
	5	13	9.8	12.1	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Pharmacologic therapy (basic mechanisms of common drugs for inflammatory disorders in airways and skin)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	0.8	0.9	0.9
	1	1	0.8	0.9	1.9
	2	8	6.0	7.5	9.3
	3	35	26.3	32.7	42.1
	4	47	35.3	43.9	86.0
	5	15	11.3	14.0	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Immunotherapy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	4	3.0	3.7	3.7
	1	23	17.3	21.5	25.2
	2	40	30.1	37.4	62.6
	3	26	19.5	24.3	86.9
	4	10	7.5	9.3	96.3
	5	4	3.0	3.7	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Environmental Control Measures[a]

	Frequency	Percentage	Valid Percentage	Cumulative Percentage

Valid	I don't see patients with this condition	2	1.5	1.9	1.9
	1	6	4.5	5.6	7.5
	2	19	14.3	17.8	25.2
	3	29	21.8	27.1	52.3
	4	41	30.8	38.3	90.7
	5	10	7.5	9.3	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Risk assessment for anaphylaxis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	1	0.8	1.0	1.0
	2	10	7.5	9.5	10.5
	3	39	29.3	37.1	47.6
	4	41	30.8	39.0	86.7
	5	14	10.5	13.3	100.0
	Total	105	78.9	100.0	
Missing	Data	28	21.1		
Total		133	100.0		

a. Country = Spain

Prescription/training of adrenaline[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	5	3.8	4.8	4.8
	2	6	4.5	5.7	10.5
	3	25	18.8	23.8	34.3
	4	47	35.3	44.8	79.0
	5	22	16.5	21.0	100.0
	Total	105	78.9	100.0	
Missing	Data	28	21.1		
Total		133	100.0		

a. Country = Spain

Identifying patients who need to be referred to an allergist a

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	2	1.5	1.9	1.9
	1	2	1.5	1.9	3.7
	2	7	5.3	6.5	10.3
	3	34	25.6	31.8	42.1
	4	49	36.8	45.8	87.9
	5	13	9.8	12.1	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Lack of knowledge of the patient's condition[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Lack of knowledge of the patient's	29	21.8	100.0	100.0
Missing	Data	104	78.2		
Total		133	100.0		

a. Country = Spain

Partial response to the first line treatment[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage

Valid	Partial response to the first line	61	45.9	100.0	100.0
Missing	Data	72	54.1		
Total		133	100.0		

a. Country = Spain

Need of differential diagnosis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Need of differential diagnosis	49	36.8	100.0	100.0
Missing	Data	84	63.2		
Total		133	100.0		

a. Country = Spain

Diagnostic uncertainty[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Diagnostic uncertainty	56	42.1	100.0	100.0
Missing	Data	77	57.9		
Total		133	100.0		

a. Country = Spain

Need of hospital assessment (anaphylaxis, venom allergy, etc.)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Need of hospital assessment (anaphylaxis, venom allergy,	89	66.9	100.0	100.0
Missing	Data	44	33.1		
Total		133	100.0		

a. Country = Spain

Other (please specify)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		124	93.2	93.2	93.2
	Conocer alérgenos. Paciente lo	1	0.8	0.8	94.0
	immunoterapia	1	0.8	0.8	94.7

	PETICION DE VALORACION POR PARTE DEL	1	0.8	0.8	95.5
	Petición expresa del paciente	1	0.8	0.8	96.2
	Precise inmunoterapia	1	0.8	0.8	97.0
	Pruebas	1	0.8	0.8	97.7
	Pruebas alérgicas	1	0.8	0.8	98.5
	Realización pruebas complementarias. Ex: Prick-	1	0.8	0.8	99.2
	SOY ENFERMERA	1	0.8	0.8	100.0
	Total	133	100.0	100.0	

a. Country = Spain

Are you aware of the GP guidelines which include guidelines for referral in your country?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	74	55.6	69.2	69.2
	Yes	33	24.8	30.8	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

Do you use these guidelines?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	1	0.8	3.0	3.0
	Yes	32	24.1	97.0	100.0
	Total	33	24.8	100.0	
Missing	Data	100	75.2		
Total		133	100.0		

a. Country = Spain

Are you aware of the EAACI competencies document for allied health professionals for allergy?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	99	74.4	92.5	92.5
	Yes	8	6.0	7.5	100.0

	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

There are no allergists in my Area/Health System a

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	There are no in my Area/Health	1	0.8	100.0	100.0
Missing	Data	132	99.2		
Total		133	100.0		

a. Country = Spain

I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I consider that the patient's condition could be diagnosed and treated in this PC facility	93	69.9	100.0	100.0
Missing	Data	40	30.1		
Total		133	100.0		

a. Country = Spain

There are too long waiting times[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	There are too long waiting times	20	15.0	100.0	100.0
Missing	Data	113	85.0		
Total		133	100.0		

a. Country = Spain

Other (please specify)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		123	92.5	92.5	92.5
	dificultad para derivar al especialista	1	0.8	0.8	93.2

	falta de movilidad y clínica poco	1	0.8	0.8	94.0
	Los envío cuando considero	1	0.8	0.8	94.7
	Los remito	1	0.8	0.8	95.5
	No derivo	1	0.8	0.8	96.2
	patología banal, episódica, bien controlada	1	0.8	0.8	97.0
	puede ser valorado por derma, orl o	1	0.8	0.8	97.7
	Que no lo	1	0.8	0.8	98.5
	Siempre los remito si sospecho alergia y no ha sido estudiado	1	0.8	0.8	99.2
	SOY ENFERMERA	1	0.8	0.8	100.0
	Total	133	100.0	100.0	

a. Country = Spain

Do you have access to immuotherapy in your practice or by referring to a specialised service?

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	42	31.6	45.2	45.2
	Yes	51	38.3	54.8	100.0
	Total	93	69.9	100.0	
Missing	Data	40	30.1		
Total		133	100.0		

a. Country = Spain

Which one of the following learning and assessment methods do you prefer?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Traditional Learning and Assessment	46	34.6	49.5	49.5
	E-Learning and on-line assessment	47	35.3	50.5	100.0
	Total	93	69.9	100.0	
Missing	Data	40	30.1		
Total		133	100.0		

a. Country = Spain

Smartphone[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	N/A	8	6.0	7.6	7.6
	1	5	3.8	4.8	12.4
	2	16	12.0	15.2	27.6
	3	15	11.3	14.3	41.9
	4	29	21.8	27.6	69.5
	5	32	24.1	30.5	100.0
	Total	105	78.9	100.0	
Missing	Data	28	21.1		
Total		133	100.0		

a. Country = Spain

Tablet[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	N/A	10	7.5	9.5	9.5
	1	2	1.5	1.9	11.4
	2	6	4.5	5.7	17.1
	3	23	17.3	21.9	39.0
	4	35	26.3	33.3	72.4
	5	29	21.8	27.6	100.0
	Total	105	78.9	100.0	
Missing	Data	28	21.1		
Total		133	100.0		

a. Country = Spain

Computer[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	N/A	6	4.5	5.7	5.7
	2	6	4.5	5.7	11.4
	3	10	7.5	9.5	21.0
	4	34	25.6	32.4	53.3
	5	49	36.8	46.7	100.0
	Total	105	78.9	100.0	
Missing	Data	28	21.1		
Total		133	100.0		

a. Country = Spain

Open-Ended Response[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		117	88.0	88.0	88.0
	—	1	0.8	0.8	88.7
	.	1	0.8	0.8	89.5
	Casos clínicos	1	0.8	0.8	90.2
	Falta contacto real Medico de Familia y Alergologo que trabajen en el mismo Departamento o Area de Salud. Visitar los centros de salud para	1	0.8	0.8	91.0
	Formació d al.lergologia en centres de treball disopsicio de protocols i guies d al.lergologia més importants de l especialitat per metges i infermera de familia	1	0.8	0.8	91.7
	Gracias por preocuparos por nuestro nivel de manejo del tema, dudas y	1	0.8	0.8	92.5
	Hay que	1	0.8	0.8	93.2
	He anotado muchos conceptos de la encuesta para investigar	1	0.8	0.8	94.0

	La formación en alergologia e immunologia durante la carrera de medicina es nula o muy escasa. El acceso más temprano a esta especialidad es durante la residencia, escongiendo alergología como optativa en caso que estés en un hospital de 3r nivel. Pienso que los médicos de atención	1	0.8	0.8	94.7
	La patologia alérgica es muy frecuente, pero en el ámbito en que trabajo hay acceso a estudios, por lo que remito a los pacientes. Cuando ya están	1	0.8	0.8	95.5
	La residencia de Medicina familiar y comunitaria debería incluir una rotación obligatoria en	1	0.8	0.8	96.2
	LOS ENFERMEROS QUE TRABAJAMOS EN UNIDADES DE ALERGIA,DEMANDAMOS LA NECESIDAD	1	0.8	0.8	97.0
	MAS FORMACION ALERGIA A	1	0.8	0.8	97.7
	No	1	0.8	0.8	98.5

	Sería interesante la creación de una app que ayude en el manejo de pacientes con	1	0.8	0.8	99.2
	Sería muy interesante que cada centro de salud pudiese hacer prick	1	0.8	0.8	100.0
	Total	133	100.0	100.0	

a. Country = Spain

AnaphylaxisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	24	18.0	23.1	23.1
	Adequate	80	60.2	76.9	100.0
	Total	104	78.2	100.0	
Missing	Data	29	21.8		
Total		133	100.0		

a. Country = Spain

RhinitisasthmaBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	13	9.8	12.3	12.3
	Adequate	93	69.9	87.7	100.0
	Total	106	79.7	100.0	
Missing	Data	27	20.3		
Total		133	100.0		

a. Country = Spain

AtopicdermatitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	39	29.3	36.8	36.8
	Adequate	67	50.4	63.2	100.0
	Total	106	79.7	100.0	
Missing	Data	27	20.3		
Total		133	100.0		

a. Country = Spain

ContactdermatitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	44	33.1	41.1	41.1
	Adequate	63	47.4	58.9	100.0
	Total	107	80.5	100.0	
Missing	Data	26	19.5		
Total		133	100.0		

a. Country = Spain

UrticariaandangioedemaBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	30	22.6	28.6	28.6
	Adequate	75	56.4	71.4	100.0
	Total	105	78.9	100.0	
Missing	Data	28	21.1		
Total		133	100.0		

a. Country = Spain

FoodallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	64	48.1	61.5	61.5
	Adequate	40	30.1	38.5	100.0
	Total	104	78.2	100.0	
Missing	Data	29	21.8		
Total		133	100.0		

a. Country = Spain

DrugallergyimmediateanddelayedBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	65	48.9	61.3	61.3
	Adequate	41	30.8	38.7	100.0
	Total	106	79.7	100.0	
Missing	Data	27	20.3		
Total		133	100.0		

a. Country = Spain

VenomallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	70	52.6	67.3	67.3
	Adequate	34	25.6	32.7	100.0
	Total	104	78.2	100.0	
Missing	Data	29	21.8		
Total		133	100.0		

a. Country = Spain

OccupationalallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	80	60.2	80.8	80.8
	Adequate	19	14.3	19.2	100.0
	Total	99	74.4	100.0	
Missing	Data	34	25.6		
Total		133	100.0		

a. Country = Spain

LatexallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	71	53.4	69.6	69.6
	Adequate	31	23.3	30.4	100.0
	Total	102	76.7	100.0	
Missing	Data	31	23.3		
Total		133	100.0		

a. Country = Spain

UnderstandingofthefollowingtermsBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	64	48.1	60.4	60.4
	Adequate	42	31.6	39.6	100.0
	Total	106	79.7	100.0	
Missing	Data	27	20.3		
Total		133	100.0		

a. Country = Spain

UnderstandingofcrossreactivityBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	58	43.6	55.2	55.2
	Adequate	47	35.3	44.8	100.0
	Total	105	78.9	100.0	
Missing	Data	28	21.1		
Total		133	100.0		

a. Country = Spain

BasicmechanismsofallergicnonallergicrhinitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	58	43.6	54.7	54.7
	Adequate	48	36.1	45.3	100.0
	Total	106	79.7	100.0	
Missing	Data	27	20.3		
Total		133	100.0		

a. Country = Spain

PharmacologictherapyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	44	33.1	41.5	41.5
	Adequate	62	46.6	58.5	100.0
	Total	106	79.7	100.0	
Missing	Data	27	20.3		
Total		133	100.0		

a. Country = Spain

ImmunotherapyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	89	66.9	86.4	86.4
	Adequate	14	10.5	13.6	100.0
	Total	103	77.4	100.0	
Missing	Data	30	22.6		
Total		133	100.0		

a. Country = Spain

EnvironmentalControlMeasuresBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage

Valid	Inadequate	54	40.6	51.4	51.4
	Adequate	51	38.3	48.6	100.0
	Total	105	78.9	100.0	
Missing	Data	28	21.1		
Total		133	100.0		

a. Country = Spain

RiskassessmentforanaphylaxisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	50	37.6	47.6	47.6
	Adequate	55	41.4	52.4	100.0
	Total	105	78.9	100.0	
Missing	Data	28	21.1		
Total		133	100.0		

a. Country = Spain

PrescriptiontrainingofadrenalineBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	36	27.1	34.3	34.3
	Adequate	69	51.9	65.7	100.0
	Total	105	78.9	100.0	
Missing	Data	28	21.1		
Total		133	100.0		

a. Country = Spain

WithregardtopatientswithapossiblediagnosisofallergicBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	43	32.3	41.0	41.0
	Adequate	62	46.6	59.0	100.0
	Total	105	78.9	100.0	
Missing	Data	28	21.1		
Total		133	100.0		

a. Country = Spain

Country = Netherlands

Demographic parameters frequency table

Age[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	25 - 34	2	3.5	3.5	3.5
	35 - 44	11	19.3	19.3	22.8
	45 - 54	23	40.4	40.4	63.2
	55 - 64	19	33.3	33.3	96.5
	65+	2	3.5	3.5	100.0
	Total	57	100.0	100.0	

a. Country = Netherlands

Gender[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Female	29	50.9	50.9	50.9
	Male	28	49.1	49.1	100.0
	Total	57	100.0	100.0	

a. Country = Netherlands

Area of practice[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Primary Care Clinician	52	91.2	91.2	91.2
	Dietician	1	1.8	1.8	93.0
	Other	4	7.0	7.0	100.0
	Total	57	100.0	100.0	

a. Country = Netherlands

In the case of being a GP with specialist interest in allergy how many hours a week do you work in this a

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I am not a GP with specialist interest in allergy	45	78.9	93.8	93.8
	0 - 8 hours	3	5.3	6.3	100.0
	Total	48	84.2	100.0	
Missing	Data	9	15.8		

Total		57	100.0		

a. Country = Netherlands

Your practice is within: (main employer)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Contracted to state or district health Service	9	15.8	16.7	16.7
	Private practice	36	63.2	66.7	83.3
	Other	9	15.8	16.7	100.0
	Total	54	94.7	100.0	
Missing	Data	3	5.3		
Total		57	100.0		

a. Country = Netherlands

How many patients per week come to see you whose MAIN complaint is an allergic problem?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	0 - 10	50	87.7	92.6	92.6
	11 - 25	3	5.3	5.6	98.1
	50 - 100	1	1.8	1.9	100.0
	Total	54	94.7	100.0	
Missing	Data	3	5.3		
Total		57	100.0		

a. Country = Netherlands

By your estimation, what percentage of patients with allergy have visited the pharmacy exclusively prior visiting you at your Primary Care facility in a year?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	0 - 10 %	5	8.8	9.3	9.3
	11 - 25 %	12	21.1	22.2	31.5
	26 - 50 %	18	31.6	33.3	64.8
	50 - 100 %	11	19.3	20.4	85.2
	I don't know	8	14.0	14.8	100.0
	Total	54	94.7	100.0	
Missing	Data	3	5.3		
Total		57	100.0		

a. Country = Netherlands

Allergy teaching as undergraduate (theoretical and practical contents)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Allergy teaching as undergraduate (theoretical and practical	43	75.4	100.0	100.0
Missing	Data	14	24.6		
Total		57	100.0		

a. Country = Netherlands

Allergy teaching as post-graduate (theoretical and practical contents)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Allergy teaching as post-graduate (theoretical	41	71.9	100.0	100.0
Missing	Data	16	28.1		
Total		57	100.0		

a. Country = Netherlands

Non of them[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	None of them	3	5.3	100.0	100.0
Missing	Data	54	94.7		
Total		57	100.0		

a. Country = Netherlands

Anaphylaxis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	1	2	3.5	3.8	5.7
	2	2	3.5	3.8	9.4
	3	2	3.5	3.8	13.2
	4	24	42.1	45.3	58.5
	5	22	38.6	41.5	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Rhinitis / asthma[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	1	2	3.5	3.8	5.7
	3	3	5.3	5.7	11.3
	4	29	50.9	54.7	66.0
	5	18	31.6	34.0	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Atopic dermatitis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	1	2	3.5	3.8	5.7
	3	7	12.3	13.2	18.9
	4	23	40.4	43.4	62.3
	5	20	35.1	37.7	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Contact dermatitis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	1	2	3.5	3.8	5.7
	2	1	1.8	1.9	7.5
	3	15	26.3	28.3	35.8
	4	24	42.1	45.3	81.1
	5	10	17.5	18.9	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		

Total		57	100.0		

a. Country = Netherlands

Urticaria and angioedema[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	1	2	3.5	3.8	5.7
	3	8	14.0	15.1	20.8
	4	25	43.9	47.2	67.9
	5	17	29.8	32.1	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Food allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	1	2	3.5	3.8	5.7
	2	13	22.8	24.5	30.2
	3	20	35.1	37.7	67.9
	4	15	26.3	28.3	96.2
	5	2	3.5	3.8	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Drug allergy (immediate and delayed)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	2	7	12.3	13.2	15.1
	3	21	36.8	39.6	54.7
	4	20	35.1	37.7	92.5
	5	4	7.0	7.5	100.0
	Total	53	93.0	100.0	

Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Venom allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	2	3.5	3.8	3.8
	1	1	1.8	1.9	5.7
	2	5	8.8	9.4	15.1
	3	14	24.6	26.4	41.5
	4	23	40.4	43.4	84.9
	5	8	14.0	15.1	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Occupational allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	1	1	1.8	1.9	3.8
	2	10	17.5	18.9	22.6
	3	29	50.9	54.7	77.4
	4	11	19.3	20.8	98.1
	5	1	1.8	1.9	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Latex allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	2	9	15.8	17.0	18.9
	3	22	38.6	41.5	60.4
	4	18	31.6	34.0	94.3

	5	3	5.3	5.7	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Understanding of terms like sensitisation, atopy, type I and type IV allergy

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	1	4	7.0	7.5	9.4
	2	8	14.0	15.1	24.5
	3	11	19.3	20.8	45.3
	4	23	40.4	43.4	88.7
	5	6	10.5	11.3	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Understanding of cross-reactivity[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	1	3	5.3	5.7	7.5
	2	12	21.1	22.6	30.2
	3	21	36.8	39.6	69.8
	4	14	24.6	26.4	96.2
	5	2	3.5	3.8	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Basic mechanisms of allergic/non-allergic rhinitis and organic disorders (for example in the nose and sinus)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9

	1	1	1.8	1.9	3.8
	2	6	10.5	11.3	15.1
	3	13	22.8	24.5	39.6
	4	28	49.1	52.8	92.5
	5	4	7.0	7.5	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Pharmacologic therapy (basic mechanisms of common drugs for inflammatory disorders in airways and skin)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	2	3	5.3	5.7	7.5
	3	6	10.5	11.3	18.9
	4	35	61.4	66.0	84.9
	5	8	14.0	15.1	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Immunotherapy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	2	3.5	3.8	3.8
	1	5	8.8	9.4	13.2
	2	19	33.3	35.8	49.1
	3	15	26.3	28.3	77.4
	4	9	15.8	17.0	94.3
	5	3	5.3	5.7	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Environmental Control Measures[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	2	5	8.8	9.4	11.3
	3	18	31.6	34.0	45.3
	4	24	42.1	45.3	90.6
	5	5	8.8	9.4	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Risk assessment for anaphylaxis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	1	3	5.3	5.7	7.5
	2	4	7.0	7.5	15.1
	3	14	24.6	26.4	41.5
	4	24	42.1	45.3	86.8
	5	7	12.3	13.2	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Prescription/training of adrenaline[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	1	4	7.0	7.5	9.4
	2	8	14.0	15.1	24.5
	3	12	21.1	22.6	47.2
	4	21	36.8	39.6	86.8
	5	7	12.3	13.2	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Identifying patients who need to be referred to an allergist

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.8	1.9	1.9
	1	1	1.8	1.9	3.8
	2	3	5.3	5.7	9.4
	3	15	26.3	28.3	37.7
	4	26	45.6	49.1	86.8
	5	7	12.3	13.2	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Lack of knowledge of the patient's condition[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Lack of knowledge of the patient's	14	24.6	100.0	100.0
Missing	Data	43	75.4		
Total		57	100.0		

a. Country = Netherlands

Partial response to the first line treatment[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Partial response to the first line	37	64.9	100.0	100.0
Missing	Data	20	35.1		
Total		57	100.0		

a. Country = Netherlands

Need of differential diagnosis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Need of differential diagnosis	22	38.6	100.0	100.0
Missing	Data	35	61.4		
Total		57	100.0		

a. Country = Netherlands

Diagnostic uncertainty[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Diagnostic uncertainty	42	73.7	100.0	100.0
Missing	Data	15	26.3		
Total		57	100.0		

a. Country = Netherlands

Need of hospital assessment (anaphylaxis, venom allergy, etc.)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Need of hospital assessment (anaphylaxis, venom allergy,	45	78.9	100.0	100.0
Missing	Data	12	21.1		
Total		57	100.0		

a. Country = Netherlands

Other (please specify)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		51	89.5	89.5	89.5
	Bij reactie op mogelijke arbeidsgerelateerde stof onvoldoende mogelijkheden	1	1.8	1.8	91.2
	Soms veeleisende patient icm met mijn niet	1	1.8	1.8	93.0
	test	1	1.8	1.8	94.7
	toegankelijkheid/beschikbaarheid (=belemmering	1	1.8	1.8	96.5
	verzoek patient	1	1.8	1.8	98.2
	Wens patient	1	1.8	1.8	100.0
	Total	57	100.0	100.0	

a. Country = Netherlands

Are you aware of the GP guidelines which include guidelines for referral in your country?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	2	3.5	3.8	3.8
	Yes	51	89.5	96.2	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Do you use these guidelines?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	12	21.1	23.5	23.5
	Yes	39	68.4	76.5	100.0
	Total	51	89.5	100.0	
Missing	Data	6	10.5		
Total		57	100.0		

a. Country = Netherlands

Are you aware of the EAACI competencies document for allied health professionals for allergy?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	52	91.2	98.1	98.1
	Yes	1	1.8	1.9	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Do you have access to allergy investigations in your Primary Care facility?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	10	17.5	18.9	18.9
	Yes	43	75.4	81.1	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

AllergySkinPrickTests[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	35	61.4	81.4	81.4
	Yes	8	14.0	18.6	100.0
	Total	43	75.4	100.0	
Missing	Data	14	24.6		
Total		57	100.0		

a. Country = Netherlands

Serum Specific IgE[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	3	5.3	7.0	7.0
	Yes	40	70.2	93.0	100.0
	Total	43	75.4	100.0	
Missing	Data	14	24.6		
Total		57	100.0		

a. Country = Netherlands

Patch Tests[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	40	70.2	93.0	93.0
	Yes	3	5.3	7.0	100.0
	Total	43	75.4	100.0	
Missing	Data	14	24.6		
Total		57	100.0		

a. Country = Netherlands

Spirometry[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	1	1.8	2.3	2.3
	Yes	42	73.7	97.7	100.0
	Total	43	75.4	100.0	
Missing	Data	14	24.6		
Total		57	100.0		

a. Country = Netherlands

FENO

		Frequency	Percentage	Valid Percentage	Cumulative Percentage

Valid	No	42	73.7	97.7	97.7
	Yes	1	1.8	2.3	100.0
	Total	43	75.4	100.0	
Missing	Data	14	24.6		
Total		57	100.0		

a. Country = Netherlands

Allergy Skin Prick Tests

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	27	47.4	62.8	62.8
	Yes	16	28.1	37.2	100.0
	Total	43	75.4	100.0	
Missing	Data	14	24.6		
Total		57	100.0		

a. Country = Netherlands

Serum Specific IgE[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	4	7.0	9.3	9.3
	Yes	39	68.4	90.7	100.0
	Total	43	75.4	100.0	
Missing	Data	14	24.6		
Total		57	100.0		

a. Country = Netherlands

Patch Tests[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	28	49.1	65.1	65.1
	Yes	15	26.3	34.9	100.0
	Total	43	75.4	100.0	
Missing	Data	14	24.6		
Total		57	100.0		

a. Country = Netherlands

FENO

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	41	71.9	95.3	95.3
	Yes	2	3.5	4.7	100.0

	Total	43	75.4	100.0	
Missing	Data	14	24.6		
Total		57	100.0		

a. Country = Netherlands

There are no allergists in my Area/Health System

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	There are no in my Area/Health	7	12.3	100.0	100.0
Missing	Data	50	87.7		
Total		57	100.0		

a. Country = Netherlands

I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I consider that the patient's condition could be diagnosed and treated in this PC facility	40	70.2	100.0	100.0
Missing	Data	17	29.8		
Total		57	100.0		

a. Country = Netherlands

There are too long waiting times[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	There are too long waiting times	20	35.1	100.0	100.0
Missing	Data	37	64.9		
Total		57	100.0		

a. Country = Netherlands

Other (please specify)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		49	86.0	86.0	86.0
	De eenvoud van de aandoening	1	1.8	1.8	87.7

	Ik Herken dit probleem niet	1	1.8	1.8	89.5
	ik verwijs wel	1	1.8	1.8	91.2
	nu geen belemmeringen, vroeger: zeer lange	1	1.8	1.8	93.0
	nvt	1	1.8	1.8	94.7
	Soms weinig consequenties voor het beleid	1	1.8	1.8	96.5
	soms weinig klinische consequenties	1	1.8	1.8	98.2
	test	1	1.8	1.8	100.0
	Total	57	100.0	100.0	

a. Country = Netherlands

Do you have access to immuotherapy in your practice or by referring to a specialised service?

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	3	5.3	5.7	5.7
	Yes	50	87.7	94.3	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Which one of the following learning and assessment methods do you prefer?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Traditional Learning and Assessment	26	45.6	49.1	49.1
	E-Learning and on-line assessment	27	47.4	50.9	100.0
	Total	53	93.0	100.0	
Missing	Data	4	7.0		
Total		57	100.0		

a. Country = Netherlands

Smartphone[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	12	21.1	24.5	24.5

	2	12	21.1	24.5	49.0
	3	11	19.3	22.4	71.4
	4	9	15.8	18.4	89.8
	5	5	8.8	10.2	100.0
	Total	49	86.0	100.0	
Missing	Data	8	14.0		
Total		57	100.0		

a. Country = Netherlands

Tablet[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	4	7.0	7.8	7.8
	2	2	3.5	3.9	11.8
	3	9	15.8	17.6	29.4
	4	24	42.1	47.1	76.5
	5	12	21.1	23.5	100.0
	Total	51	89.5	100.0	
Missing	Data	6	10.5		
Total		57	100.0		

a. Country = Netherlands

Computer[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	2	2	3.5	3.8	3.8
	3	2	3.5	3.8	7.7
	4	23	40.4	44.2	51.9
	5	25	43.9	48.1	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

Open-Ended Response[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		48	84.2	84.2	84.2
	-	1	1.8	1.8	86.0
	.	1	1.8	1.8	87.7

	Allergie is vaak goed te behandelen in de 1e lijn. Soms is er verwijzing voor nodig. Helaas duurt het dan veel te lang voor iemand echt bij een allergoloog	1	1.8	1.8	89.5
	b	1	1.8	1.8	91.2
	geen	2	3.5	3.5	94.7
	mn de gecompliceerde allergie is moeilijk echter merendeel in ha praktijk is enkelvoudig en	1	1.8	1.8	96.5
	test by Bertine	1	1.8	1.8	98.2
	wat een rare vragenlijst, vooral de start. NL heeft geen privépraktijken. Wie heeft deze lijst bedacht?	1	1.8	1.8	100.0
	Total	57	100.0	100.0	

a. Country = Netherlands

AnaphylaxisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	6	10.5	11.5	11.5
	Adequate	46	80.7	88.5	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

RhinitisasthmaBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	5	8.8	9.6	9.6
	Adequate	47	82.5	90.4	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		

Total		57	100.0		

a. Country = Netherlands

AtopicdermatitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	9	15.8	17.3	17.3
	Adequate	43	75.4	82.7	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

ContactdermatitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	18	31.6	34.6	34.6
	Adequate	34	59.6	65.4	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

UrticariaandangioedemaBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	10	17.5	19.2	19.2
	Adequate	42	73.7	80.8	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

FoodallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	35	61.4	67.3	67.3
	Adequate	17	29.8	32.7	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

DrugallergyimmediateanddelayedBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	28	49.1	53.8	53.8
	Adequate	24	42.1	46.2	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

VenomallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	20	35.1	39.2	39.2
	Adequate	31	54.4	60.8	100.0
	Total	51	89.5	100.0	
Missing	Data	6	10.5		
Total		57	100.0		

a. Country = Netherlands

OccupationalallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	40	70.2	76.9	76.9
	Adequate	12	21.1	23.1	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

LatexallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	31	54.4	59.6	59.6
	Adequate	21	36.8	40.4	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

UnderstandingofthefollowingtermsBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	23	40.4	44.2	44.2
	Adequate	29	50.9	55.8	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

UnderstandingofcrossreactivityBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	36	63.2	69.2	69.2
	Adequate	16	28.1	30.8	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

BasicmechanismsofallergicnonallergicrhinitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	20	35.1	38.5	38.5
	Adequate	32	56.1	61.5	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

PharmacologictherapyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	9	15.8	17.3	17.3
	Adequate	43	75.4	82.7	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

ImmunotherapyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	39	68.4	76.5	76.5
	Adequate	12	21.1	23.5	100.0
	Total	51	89.5	100.0	
Missing	Data	6	10.5		
Total		57	100.0		

a. Country = Netherlands

EnvironmentalControlMeasuresBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	23	40.4	44.2	44.2
	Adequate	29	50.9	55.8	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

RiskassessmentforanaphylaxisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	21	36.8	40.4	40.4
	Adequate	31	54.4	59.6	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

PrescriptiontrainingofadrenalineBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	24	42.1	46.2	46.2
	Adequate	28	49.1	53.8	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

WithregardtopatientswithapossiblediagnosisofallergicBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage

Valid	Inadequate	19	33.3	36.5	36.5
	Adequate	33	57.9	63.5	100.0
	Total	52	91.2	100.0	
Missing	Data	5	8.8		
Total		57	100.0		

a. Country = Netherlands

Country = Poland

Demographic parameters frequency table

Age[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	25 - 34	54	78.3	78.3	78.3
	35 - 44	14	20.3	20.3	98.6
	45 - 54	1	1.4	1.4	100.0
	Total	69	100.0	100.0	

a. Country = Poland

Gender[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Female	54	78.3	78.3	78.3
	Male	15	21.7	21.7	100.0
	Total	69	100.0	100.0	

a. Country = Poland

Area of practice[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Primary Care Clinician	63	91.3	91.3	91.3
	Pediatrician	4	5.8	5.8	97.1
	Other	2	2.9	2.9	100.0
	Total	69	100.0	100.0	

a. Country = Poland

In the case of being a GP with specialist interest in allergy how many hours a week do you work in this

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	0 - 8 hours	53	76.8	86.9	86.9
	8 - 16 hours	5	7.2	8.2	95.1
	16 - 24 hours	1	1.4	1.6	96.7
	24 - 32 hours	1	1.4	1.6	98.4
	32 - 40 hours	1	1.4	1.6	100.0
	Total	61	88.4	100.0	
Missing	Data	8	11.6		

Total		69	100.0		

a. Country = Poland

Your practice is within: (main employer)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Contracted to state or district health Service	35	50.7	57.4	57.4
	Private practice	5	7.2	8.2	65.6
	University, college or equivalent	2	2.9	3.3	68.9
	Other	19	27.5	31.1	100.0
	Total	61	88.4	100.0	
Missing	Data	8	11.6		
Total		69	100.0		

a. Country = Poland

How many patients per week come to see you whose MAIN complaint is an allergic problem?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	0 - 10	37	53.6	60.7	60.7
	11 - 25	19	27.5	31.1	91.8
	26 - 50	5	7.2	8.2	100.0
	Total	61	88.4	100.0	
Missing	Data	8	11.6		
Total		69	100.0		

a. Country = Poland

By your estimation, what percentage of patients with allergy have visited the pharmacy exclusively prior visiting you at your Primary Care facility in a year?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	0 - 10 %	13	18.8	21.3	21.3
	11 - 25 %	19	27.5	31.1	52.5
	26 - 50 %	17	24.6	27.9	80.3
	50 - 100 %	8	11.6	13.1	93.4
	I don't know	4	5.8	6.6	100.0
	Total	61	88.4	100.0	
Missing	Data	8	11.6		

Total		69	100.0		

a. Country = Poland

Allergy teaching as undergraduate (theoretical and practical contents)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Allergy teaching as undergraduate (theoretical and practical	54	78.3	100.0	100.0
Missing	Data	15	21.7		
Total		69	100.0		

a. Country = Poland

Allergy teaching as post-graduate (theoretical and practical contents)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Allergy teaching as post-graduate (theoretical	47	68.1	100.0	100.0
Missing	Data	22	31.9		
Total		69	100.0		

a. Country = Poland

Non of them[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	None of them	1	1.4	100.0	100.0
Missing	Data	68	98.6		
Total		69	100.0		

a. Country = Poland

Anaphylaxis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	2	2.9	4.8	4.8
	1	1	1.4	2.4	7.1
	3	8	11.6	19.0	26.2
	4	16	23.2	38.1	64.3
	5	15	21.7	35.7	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		

Total		69	100.0		

a. Country = Poland

Rhinitis / asthma[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	1	1.4	2.4	2.4
	3	6	8.7	14.3	16.7
	4	20	29.0	47.6	64.3
	5	15	21.7	35.7	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Atopic dermatitis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	2	6	8.7	14.3	14.3
	3	12	17.4	28.6	42.9
	4	16	23.2	38.1	81.0
	5	8	11.6	19.0	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Contact dermatitis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	2	7	10.1	16.7	16.7
	3	16	23.2	38.1	54.8
	4	16	23.2	38.1	92.9
	5	3	4.3	7.1	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Urticaria and angioedema[a]

	Frequency	Percentage	Valid Percentage	Cumulative Percentage

Valid	1	1	1.4	2.4	2.4
	2	3	4.3	7.1	9.5
	3	4	5.8	9.5	19.0
	4	27	39.1	64.3	83.3
	5	7	10.1	16.7	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Food allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	2	9	13.0	21.4	21.4
	3	19	27.5	45.2	66.7
	4	9	13.0	21.4	88.1
	5	5	7.2	11.9	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Drug allergy (immediate and delayed)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	1	1.4	2.4	2.4
	2	5	7.2	11.9	14.3
	3	20	29.0	47.6	61.9
	4	12	17.4	28.6	90.5
	5	4	5.8	9.5	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Venom allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.4	2.4	2.4
	1	1	1.4	2.4	4.8
	2	1	1.4	2.4	7.1

	3	11	15.9	26.2	33.3
	4	18	26.1	42.9	76.2
	5	10	14.5	23.8	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Occupational allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	6	8.7	14.3	14.3
	1	3	4.3	7.1	21.4
	2	12	17.4	28.6	50.0
	3	12	17.4	28.6	78.6
	4	8	11.6	19.0	97.6
	5	1	1.4	2.4	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Latex allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	4	5.8	9.5	9.5
	1	2	2.9	4.8	14.3
	2	10	14.5	23.8	38.1
	3	19	27.5	45.2	83.3
	4	7	10.1	16.7	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Understanding of terms like sensitisation, atopy, type I and type IV allergy

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	1	1.4	2.4	2.4

	2	4	5.8	9.5	11.9
	3	9	13.0	21.4	33.3
	4	17	24.6	40.5	73.8
	5	11	15.9	26.2	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Understanding of cross-reactivity[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	3	4.3	7.1	7.1
	2	11	15.9	26.2	33.3
	3	22	31.9	52.4	85.7
	4	5	7.2	11.9	97.6
	5	1	1.4	2.4	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Basic mechanisms of allergic/non-allergic rhinitis and organic disorders (for example in the nose and sinus)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	1	1.4	2.4	2.4
	2	5	7.2	11.9	14.3
	3	10	14.5	23.8	38.1
	4	22	31.9	52.4	90.5
	5	4	5.8	9.5	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Pharmacologic therapy (basic mechanisms of common drugs for inflammatory disorders in airways and skin)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	2	1	1.4	2.4	2.4
	3	7	10.1	16.7	19.0

	4	24	34.8	57.1	76.2
	5	10	14.5	23.8	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Immunotherapy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	7	10.1	16.7	16.7
	2	21	30.4	50.0	66.7
	3	10	14.5	23.8	90.5
	4	4	5.8	9.5	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Environmental Control Measures[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	5	7.2	11.9	11.9
	2	9	13.0	21.4	33.3
	3	19	27.5	45.2	78.6
	4	8	11.6	19.0	97.6
	5	1	1.4	2.4	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Risk assessment for anaphylaxis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	1	1.4	2.4	2.4
	2	3	4.3	7.1	9.5
	3	16	23.2	38.1	47.6
	4	17	24.6	40.5	88.1
	5	5	7.2	11.9	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		

Total		69	100.0		

a. Country = Poland

Prescription/training of adrenaline[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	1	1.4	2.4	2.4
	2	1	1.4	2.4	4.8
	3	13	18.8	31.0	35.7
	4	15	21.7	35.7	71.4
	5	12	17.4	28.6	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Identifying patients who need to be referred to an allergist

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	2	2	2.9	4.8	4.8
	3	4	5.8	9.5	14.3
	4	27	39.1	64.3	78.6
	5	9	13.0	21.4	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Lack of knowledge of the patient's condition[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Lack of knowledge of the patient's	2	2.9	100.0	100.0
Missing	Data	67	97.1		
Total		69	100.0		

a. Country = Poland

Partial response to the first line treatment[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Partial response to the first line	28	40.6	100.0	100.0

Missing	Data	41	59.4		
Total		69	100.0		

a. Country = Poland

Need of differential diagnosis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Need of differential diagnosis	33	47.8	100.0	100.0
Missing	Data	36	52.2		
Total		69	100.0		

a. Country = Poland

Diagnostic uncertainty[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Diagnostic uncertainty	10	14.5	100.0	100.0
Missing	Data	59	85.5		
Total		69	100.0		

a. Country = Poland

Need of hospital assessment (anaphylaxis, venom allergy, etc.)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Need of hospital assessment (anaphylaxis, venom allergy,	20	29.0	100.0	100.0
Missing	Data	49	71.0		
Total		69	100.0		

a. Country = Poland

Other (please specify)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		66	95.7	95.7	95.7
	Diagnostyka niedostępna w POZ (TS	1	1.4	1.4	97.1
	Konieczność wykonania badan specjalistyczny	1	1.4	1.4	98.6

	Potrzeba potwierdzenia rozpoznania, zasiwadczenie o chorobie -	1	1.4	1.4	100.0
	Total	69	100.0	100.0	

a. Country = Poland

Are you aware of the GP guidelines which include guidelines for referral in your country?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	16	23.2	38.1	38.1
	Yes	26	37.7	61.9	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Do you use these guidelines?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	5	7.2	19.2	19.2
	Yes	21	30.4	80.8	100.0
	Total	26	37.7	100.0	
Missing	Data	43	62.3		
Total		69	100.0		

a. Country = Poland

Are you aware of the EAACI competencies document for allied health professionals for allergy?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	38	55.1	90.5	90.5
	Yes	4	5.8	9.5	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Do you have access to allergy investigations in your Primary Care facility?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	40	58.0	95.2	95.2
	Yes	2	2.9	4.8	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

AllergySkinPrickTests[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	2	2.9	100.0	100.0
Missing	Data	67	97.1		
Total		69	100.0		

a. Country = Poland

Serum Specific IgE[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	2	2.9	100.0	100.0
Missing	Data	67	97.1		
Total		69	100.0		

a. Country = Poland

Patch Tests[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	2	2.9	100.0	100.0
Missing	Data	67	97.1		
Total		69	100.0		

a. Country = Poland

Spirometry[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Yes	2	2.9	100.0	100.0
Missing	Data	67	97.1		
Total		69	100.0		

a. Country = Poland

FENO

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	2	2.9	100.0	100.0
Missing	Data	67	97.1		
Total		69	100.0		

a. Country = Poland

Allergy Skin Prick Tests

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	2	2.9	100.0	100.0
Missing	Data	67	97.1		
Total		69	100.0		

a. Country = Poland

Serum Specific IgE[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	2	2.9	100.0	100.0
Missing	Data	67	97.1		
Total		69	100.0		

a. Country = Poland

Patch Tests[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	2	2.9	100.0	100.0
Missing	Data	67	97.1		
Total		69	100.0		

a. Country = Poland

FENO

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	2	2.9	100.0	100.0
Missing	Data	67	97.1		
Total		69	100.0		

a. Country = Poland

There are no allergists in my Area/Health System

		Frequency	Percentage	Valid Percentage	Cumulative Percentage

Valid	There are no in my Area/Health	10	14.5	100.0	100.0
Missing	Data	59	85.5		
Total		69	100.0		

a. Country = Poland

I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I consider that the patient's condition could be diagnosed and treated in this PC facility	27	39.1	100.0	100.0
Missing	Data	42	60.9		
Total		69	100.0		

a. Country = Poland

There are too long waiting times[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	There are too long waiting times	20	29.0	100.0	100.0
Missing	Data	49	71.0		
Total		69	100.0		

a. Country = Poland

Other (please specify)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		66	95.7	95.7	95.7
	Nasilenie dolegliwości pacjenta	1	1.4	1.4	97.1
	Proste przypadki można leczyć z	1	1.4	1.4	98.6
	Zawsze odsyłam w razie	1	1.4	1.4	100.0
	Total	69	100.0	100.0	

a. Country = Poland

Do you have access to immuotherapy in your practice or by referring to a specialised service?

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	23	33.3	54.8	54.8
	Yes	19	27.5	45.2	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Which one of the following learning and assessment methods do you prefer?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Traditional Learning and Assessment	30	43.5	71.4	71.4
	E-Learning and on-line assessment	12	17.4	28.6	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Smartphone[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	2	2.9	4.8	4.8
	2	3	4.3	7.1	11.9
	3	4	5.8	9.5	21.4
	4	12	17.4	28.6	50.0
	5	21	30.4	50.0	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Tablet[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	19	27.5	45.2	45.2
	2	6	8.7	14.3	59.5
	3	6	8.7	14.3	73.8

	4	5	7.2	11.9	85.7
	5	6	8.7	14.3	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Computer[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	2	2.9	4.8	4.8
	2	3	4.3	7.1	11.9
	3	6	8.7	14.3	26.2
	4	12	17.4	28.6	54.8
	5	19	27.5	45.2	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Open-Ended Response[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		65	94.2	94.2	94.2
	.	1	1.4	1.4	95.7
	...	1	1.4	1.4	97.1
	Brak	1	1.4	1.4	98.6
	Wazny temat	1	1.4	1.4	100.0
	Total	69	100.0	100.0	

a. Country = Poland

AnaphylaxisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	9	13.0	22.5	22.5
	Adequate	31	44.9	77.5	100.0
	Total	40	58.0	100.0	
Missing	Data	29	42.0		
Total		69	100.0		

a. Country = Poland

RhinitisasthmaBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	7	10.1	16.7	16.7
	Adequate	35	50.7	83.3	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

AtopicdermatitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	18	26.1	42.9	42.9
	Adequate	24	34.8	57.1	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

ContactdermatitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	23	33.3	54.8	54.8
	Adequate	19	27.5	45.2	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

UrticariaandangioedemaBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	8	11.6	19.0	19.0
	Adequate	34	49.3	81.0	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

FoodallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	28	40.6	66.7	66.7
	Adequate	14	20.3	33.3	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

DrugallergyimmediateanddelayedBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	26	37.7	61.9	61.9
	Adequate	16	23.2	38.1	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

VenomallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	13	18.8	31.7	31.7
	Adequate	28	40.6	68.3	100.0
	Total	41	59.4	100.0	
Missing	Data	28	40.6		
Total		69	100.0		

a. Country = Poland

OccupationalallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	27	39.1	75.0	75.0
	Adequate	9	13.0	25.0	100.0
	Total	36	52.2	100.0	
Missing	Data	33	47.8		
Total		69	100.0		

a. Country = Poland

LatexallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage

Valid	Inadequate	31	44.9	81.6	81.6
	Adequate	7	10.1	18.4	100.0
	Total	38	55.1	100.0	
Missing	Data	31	44.9		
Total		69	100.0		

a. Country = Poland

UnderstandingofthefollowingtermsBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	14	20.3	33.3	33.3
	Adequate	28	40.6	66.7	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

UnderstandingofcrossreactivityBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	36	52.2	85.7	85.7
	Adequate	6	8.7	14.3	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

BasicmechanismsofallergicnonallergicrhinitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	16	23.2	38.1	38.1
	Adequate	26	37.7	61.9	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

PharmacologictherapyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	8	11.6	19.0	19.0
	Adequate	34	49.3	81.0	100.0

	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

ImmunotherapyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	38	55.1	90.5	90.5
	Adequate	4	5.8	9.5	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

EnvironmentalControlMeasuresBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	33	47.8	78.6	78.6
	Adequate	9	13.0	21.4	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

RiskassessmentforanaphylaxisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	20	29.0	47.6	47.6
	Adequate	22	31.9	52.4	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

PrescriptiontrainingofadrenalineBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	15	21.7	35.7	35.7
	Adequate	27	39.1	64.3	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		

Total		69	100.0		

a. Country = Poland

Withregardtopatientswithapossiblediagnosisofallergic Bin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	6	8.7	14.3	14.3
	Adequate	36	52.2	85.7	100.0
	Total	42	60.9	100.0	
Missing	Data	27	39.1		
Total		69	100.0		

a. Country = Poland

Country = Italy

Demographic oarameters frequency table

Age[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	25 - 34	2	2.4	2.4	2.4
	35 - 44	12	14.5	14.5	16.9
	45 - 54	15	18.1	18.1	34.9
	55 - 64	35	42.2	42.2	77.1
	65+	19	22.9	22.9	100.0
	Total	83	100.0	100.0	

a. Country = Italy

Gender[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Female	32	38.6	38.6	38.6
	Male	51	61.4	61.4	100.0
	Total	83	100.0	100.0	

a. Country = Italy

Area of practice[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Primary Care Clinician	62	74.7	74.7	74.7
	Primary Care Clinician with an interest in	7	8.4	8.4	83.1
	General Medical Specialist	8	9.6	9.6	92.8
	Pediatrician	4	4.8	4.8	97.6
	General Nurse	1	1.2	1.2	98.8
	Other	1	1.2	1.2	100.0
	Total	83	100.0	100.0	

a. Country = Italy

In the case of being a GP with specialist interest in allergy how many hours a week do you work in this

	Frequency	Percentage	Valid Percentage	Cumulative Percentage

Valid	I am not a GP with specialist interest in allergy	28	33.7	37.3	37.3
	0 - 8 hours	37	44.6	49.3	86.7
	8 - 16 hours	4	4.8	5.3	92.0
	16 - 24 hours	5	6.0	6.7	98.7
	24 - 32 hours	1	1.2	1.3	100.0
	Total	75	90.4	100.0	
Missing	Data	8	9.6		
Total		83	100.0		

a. Country = Italy

Your practice is within: (main employer)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Contracted to state or district health Service	77	92.8	93.9	93.9
	Private practice	3	3.6	3.7	97.6
	Retired, not currently working	1	1.2	1.2	98.8
	Other	1	1.2	1.2	100.0
	Total	82	98.8	100.0	
Missing	Data	1	1.2		
Total		83	100.0		

a. Country = Italy

How many patients per week come to see you whose MAIN complaint is an allergic problem?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	0 - 10	67	80.7	83.8	83.8
	11 - 25	12	14.5	15.0	98.8
	26 - 50	1	1.2	1.3	100.0
	Total	80	96.4	100.0	
Missing	Data	3	3.6		
Total		83	100.0		

a. Country = Italy

By your estimation, what percentage of patients with allergy have visited the pharmacy exclusively prior visiting you at your Primary Care facility in a year?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	0 - 10 %	39	47.0	48.1	48.1
	11 - 25 %	18	21.7	22.2	70.4
	26 - 50 %	8	9.6	9.9	80.2
	50 - 100 %	6	7.2	7.4	87.7
	I don't know	10	12.0	12.3	100.0
	Total	81	97.6	100.0	
Missing	Data	2	2.4		
Total		83	100.0		

a. Country = Italy

Allergy teaching as undergraduate (theoretical and practical contents)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Allergy teaching as undergraduate (theoretical and practical	13	15.7	100.0	100.0
Missing	Data	70	84.3		
Total		83	100.0		

a. Country = Italy

Allergy teaching as post-graduate (theoretical and practical contents)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Allergy teaching as post-graduate (theoretical	37	44.6	100.0	100.0
Missing	Data	46	55.4		
Total		83	100.0		

a. Country = Italy

Non of them[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	None of them	18	21.7	100.0	100.0
Missing	Data	65	78.3		
Total		83	100.0		

a. Country = Italy

Anaphylaxis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	13	15.7	18.1	18.1
	1	8	9.6	11.1	29.2
	2	11	13.3	15.3	44.4
	3	15	18.1	20.8	65.3
	4	6	7.2	8.3	73.6
	5	19	22.9	26.4	100.0
	Total	72	86.7	100.0	
Missing	Data	11	13.3		
Total		83	100.0		

a. Country = Italy

Rhinitis / asthma[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.2	1.2	1.2
	1	2	2.4	2.4	3.6
	2	6	7.2	7.2	10.8
	3	16	19.3	19.3	30.1
	4	21	25.3	25.3	55.4
	5	37	44.6	44.6	100.0
	Total	83	100.0	100.0	

a. Country = Italy

Atopic dermatitis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.2	1.2	1.2
	1	3	3.6	3.7	4.9
	2	15	18.1	18.3	23.2
	3	22	26.5	26.8	50.0
	4	19	22.9	23.2	73.2
	5	22	26.5	26.8	100.0
	Total	82	98.8	100.0	
Missing	Data	1	1.2		
Total		83	100.0		

a. Country = Italy

Contact dermatitis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.2	1.2	1.2
	1	3	3.6	3.7	4.9
	2	15	18.1	18.3	23.2
	3	22	26.5	26.8	50.0
	4	18	21.7	22.0	72.0
	5	23	27.7	28.0	100.0
	Total	82	98.8	100.0	
Missing	Data	1	1.2		
Total		83	100.0		

a. Country = Italy

Urticaria and angioedema[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.2	1.3	1.3
	1	5	6.0	6.3	7.5
	2	8	9.6	10.0	17.5
	3	24	28.9	30.0	47.5
	4	22	26.5	27.5	75.0
	5	20	24.1	25.0	100.0
	Total	80	96.4	100.0	
Missing	Data	3	3.6		
Total		83	100.0		

a. Country = Italy

Food allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.2	1.2	1.2
	1	6	7.2	7.3	8.5
	2	14	16.9	17.1	25.6
	3	31	37.3	37.8	63.4
	4	14	16.9	17.1	80.5
	5	16	19.3	19.5	100.0
	Total	82	98.8	100.0	

Missing	Data	1	1.2		
Total		83	100.0		

a. Country = Italy

Drug allergy (immediate and delayed)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	2	2.4	2.5	2.5
	1	7	8.4	8.8	11.3
	2	15	18.1	18.8	30.0
	3	17	20.5	21.3	51.3
	4	19	22.9	23.8	75.0
	5	20	24.1	25.0	100.0
	Total	80	96.4	100.0	
Missing	Data	3	3.6		
Total		83	100.0		

a. Country = Italy

Venom allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	13	15.7	16.3	16.3
	1	13	15.7	16.3	32.5
	2	14	16.9	17.5	50.0
	3	15	18.1	18.8	68.8
	4	12	14.5	15.0	83.8
	5	13	15.7	16.3	100.0
	Total	80	96.4	100.0	
Missing	Data	3	3.6		
Total		83	100.0		

a. Country = Italy

Occupational allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	12	14.5	14.8	14.8
	1	19	22.9	23.5	38.3
	2	13	15.7	16.0	54.3
	3	18	21.7	22.2	76.5

	4	13	15.7	16.0	92.6
	5	6	7.2	7.4	100.0
	Total	81	97.6	100.0	
Missing	Data	2	2.4		
Total		83	100.0		

a. Country = Italy

Latex allergy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	4	4.8	5.0	5.0
	1	12	14.5	15.0	20.0
	2	11	13.3	13.8	33.8
	3	20	24.1	25.0	58.8
	4	17	20.5	21.3	80.0
	5	16	19.3	20.0	100.0
	Total	80	96.4	100.0	
Missing	Data	3	3.6		
Total		83	100.0		

a. Country = Italy

Understanding of terms like sensitisation, atopy, type I and type IV allergy

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	3	3.6	3.7	3.7
	1	12	14.5	14.8	18.5
	2	16	19.3	19.8	38.3
	3	17	20.5	21.0	59.3
	4	10	12.0	12.3	71.6
	5	23	27.7	28.4	100.0
	Total	81	97.6	100.0	
Missing	Data	2	2.4		
Total		83	100.0		

a. Country = Italy

Understanding of cross-reactivity[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	5	6.0	6.2	6.2

	1	16	19.3	19.8	25.9
	2	15	18.1	18.5	44.4
	3	22	26.5	27.2	71.6
	4	13	15.7	16.0	87.7
	5	10	12.0	12.3	100.0
	Total	81	97.6	100.0	
Missing	Data	2	2.4		
Total		83	100.0		

a. Country = Italy

Basic mechanisms of allergic/non-allergic rhinitis and organic disorders (for example in the nose and sinus)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.2	1.3	1.3
	1	4	4.8	5.0	6.3
	2	21	25.3	26.3	32.5
	3	20	24.1	25.0	57.5
	4	17	20.5	21.3	78.8
	5	17	20.5	21.3	100.0
	Total	80	96.4	100.0	
Missing	Data	3	3.6		
Total		83	100.0		

a. Country = Italy

Pharmacologic therapy (basic mechanisms of common drugs for inflammatory disorders in airways and skin)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	4	4.8	4.9	4.9
	2	10	12.0	12.3	17.3
	3	20	24.1	24.7	42.0
	4	27	32.5	33.3	75.3
	5	20	24.1	24.7	100.0
	Total	81	97.6	100.0	
Missing	Data	2	2.4		
Total		83	100.0		

a. Country = Italy

Immunotherapy[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	2	2.4	2.4	2.4
	1	16	19.3	19.5	22.0
	2	17	20.5	20.7	42.7
	3	24	28.9	29.3	72.0
	4	9	10.8	11.0	82.9
	5	14	16.9	17.1	100.0
	Total	82	98.8	100.0	
Missing	Data	1	1.2		
Total		83	100.0		

a. Country = Italy

Environmental Control Measures[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.2	1.2	1.2
	1	8	9.6	9.9	11.1
	2	20	24.1	24.7	35.8
	3	21	25.3	25.9	61.7
	4	11	13.3	13.6	75.3
	5	20	24.1	24.7	100.0
	Total	81	97.6	100.0	
Missing	Data	2	2.4		
Total		83	100.0		

a. Country = Italy

Risk assessment for anaphylaxis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	2	2.4	2.5	2.5
	1	12	14.5	14.8	17.3
	2	16	19.3	19.8	37.0
	3	21	25.3	25.9	63.0
	4	20	24.1	24.7	87.7
	5	10	12.0	12.3	100.0
	Total	81	97.6	100.0	
Missing	Data	2	2.4		
Total		83	100.0		

a. Country = Italy

Prescription/training of adrenaline[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	9	10.8	11.1	11.1
	1	26	31.3	32.1	43.2
	2	14	16.9	17.3	60.5
	3	16	19.3	19.8	80.2
	4	9	10.8	11.1	91.4
	5	7	8.4	8.6	100.0
	Total	81	97.6	100.0	
Missing	Data	2	2.4		
Total		83	100.0		

a. Country = Italy

Identifying patients who need to be referred to an allergist

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I don't see patients with this condition	1	1.2	1.2	1.2
	1	1	1.2	1.2	2.5
	2	8	9.6	9.9	12.3
	3	14	16.9	17.3	29.6
	4	28	33.7	34.6	64.2
	5	29	34.9	35.8	100.0
	Total	81	97.6	100.0	
Missing	Data	2	2.4		
Total		83	100.0		

a. Country = Italy

Lack of knowledge of the patient's condition[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Lack of knowledge of the patient's	5	6.0	100.0	100.0
Missing	Data	78	94.0		
Total		83	100.0		

a. Country = Italy

Partial response to the first line treatment[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Partial response to the first line	28	33.7	100.0	100.0
Missing	Data	55	66.3		
Total		83	100.0		

a. Country = Italy

Need of differential diagnosis[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Need of differential diagnosis	35	42.2	100.0	100.0
Missing	Data	48	57.8		
Total		83	100.0		

a. Country = Italy

Diagnostic uncertainty[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Diagnostic uncertainty	38	45.8	100.0	100.0
Missing	Data	45	54.2		
Total		83	100.0		

a. Country = Italy

Need of hospital assessment (anaphylaxis, venom allergy, etc.)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Need of hospital assessment (anaphylaxis, venom allergy,	26	31.3	100.0	100.0
Missing	Data	57	68.7		
Total		83	100.0		

a. Country = Italy

Other (please specify)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		83	100.0	100.0	100.0

a. Country = Italy

Are you aware of the GP guidelines which include guidelines for referral in your country?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	10	12.0	33.3	33.3
	Yes	20	24.1	66.7	100.0
	Total	30	36.1	100.0	
Missing	Data	53	63.9		
Total		83	100.0		

a. Country = Italy

Do you use these guidelines?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	8	9.6	32.0	32.0
	Yes	17	20.5	68.0	100.0
	Total	25	30.1	100.0	
Missing	Data	58	69.9		
Total		83	100.0		

a. Country = Italy

Are you aware of the EAACI competencies document for allied health professionals for allergy?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	55	66.3	94.8	94.8
	Yes	3	3.6	5.2	100.0
	Total	58	69.9	100.0	
Missing	Data	25	30.1		
Total		83	100.0		

a. Country = Italy

Do you have access to allergy investigations in your Primary Care facility?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	65	78.3	90.3	90.3
	Yes	7	8.4	9.7	100.0
	Total	72	86.7	100.0	
Missing	Data	11	13.3		

Total		83	100.0		

a. Country = Italy

AllergySkinPrickTests[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	46	55.4	76.7	76.7
	Yes	14	16.9	23.3	100.0
	Total	60	72.3	100.0	
Missing	Data	23	27.7		
Total		83	100.0		

a. Country = Italy

Serum Specific IgE[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	48	57.8	76.2	76.2
	Yes	15	18.1	23.8	100.0
	Total	63	75.9	100.0	
Missing	Data	20	24.1		
Total		83	100.0		

a. Country = Italy

Patch Tests[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	49	59.0	80.3	80.3
	Yes	12	14.5	19.7	100.0
	Total	61	73.5	100.0	
Missing	Data	22	26.5		
Total		83	100.0		

a. Country = Italy

Spirometry[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	47	56.6	73.4	73.4
	Yes	17	20.5	26.6	100.0
	Total	64	77.1	100.0	
Missing	Data	19	22.9		
Total		83	100.0		

a. Country = Italy

FENO

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	54	65.1	94.7	94.7
	Yes	3	3.6	5.3	100.0
	Total	57	68.7	100.0	
Missing	Data	26	31.3		
Total		83	100.0		

a. Country = Italy

Allergy Skin Prick Tests

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	26	31.3	42.6	42.6
	Yes	35	42.2	57.4	100.0
	Total	61	73.5	100.0	
Missing	Data	22	26.5		
Total		83	100.0		

a. Country = Italy

Serum Specific IgE[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	25	30.1	41.7	41.7
	Yes	35	42.2	58.3	100.0
	Total	60	72.3	100.0	
Missing	Data	23	27.7		
Total		83	100.0		

a. Country = Italy

Patch Tests[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	31	37.3	50.8	50.8
	Yes	30	36.1	49.2	100.0
	Total	61	73.5	100.0	
Missing	Data	22	26.5		
Total		83	100.0		

a. Country = Italy

FENO

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	39	47.0	63.9	63.9
	Yes	22	26.5	36.1	100.0
	Total	61	73.5	100.0	
Missing	Data	22	26.5		
Total		83	100.0		

a. Country = Italy

There are no allergists in my Area/Health System

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	There are no in my Area/Health	9	10.8	100.0	100.0
Missing	Data	74	89.2		
Total		83	100.0		

a. Country = Italy

I consider that the patient's condition could be diagnosed and treated in this PC facility (properly addressed)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	I consider that the patient's condition could be diagnosed and treated in this PC facility	11	13.3	100.0	100.0
Missing	Data	72	86.7		
Total		83	100.0		

a. Country = Italy

There are too long waiting times[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	There are too long waiting times	7	8.4	100.0	100.0
Missing	Data	76	91.6		
Total		83	100.0		

a. Country = Italy

Other (please specify)[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid		83	100.0	100.0	100.0

a. Country = Italy

Do you have access to immuotherapy in your practice or by referring to a specialised service?

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	No	66	79.5	82.5	82.5
	Yes	14	16.9	17.5	100.0
	Total	80	96.4	100.0	
Missing	Data	3	3.6		
Total		83	100.0		

a. Country = Italy

Which one of the following learning and assessment methods do you prefer?[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Traditional Learning and Assessment	59	71.1	74.7	74.7
	E-Learning and on-line assessment	20	24.1	25.3	100.0
	Total	79	95.2	100.0	
Missing	Data	4	4.8		
Total		83	100.0		

a. Country = Italy

Smartphone[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	18	21.7	25.0	25.0
	2	9	10.8	12.5	37.5
	3	16	19.3	22.2	59.7
	4	15	18.1	20.8	80.6
	5	14	16.9	19.4	100.0
	Total	72	86.7	100.0	
Missing	Data	11	13.3		
Total		83	100.0		

a. Country = Italy

Tablet[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	17	20.5	39.5	39.5
	2	1	1.2	2.3	41.9
	3	6	7.2	14.0	55.8
	4	10	12.0	23.3	79.1
	5	9	10.8	20.9	100.0
	Total	43	51.8	100.0	
Missing	Data	40	48.2		
Total		83	100.0		

a. Country = Italy

Computer[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	1	6	7.2	11.5	11.5
	2	1	1.2	1.9	13.5
	3	7	8.4	13.5	26.9
	4	6	7.2	11.5	38.5
	5	32	38.6	61.5	100.0
	Total	52	62.7	100.0	
Missing	Data	31	37.3		
Total		83	100.0		

a. Country = Italy

Open-Ended Response[a]

	Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	83	100.0	100.0	100.0

a. Country = Italy

AnaphylaxisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	34	41.0	57.6	57.6
	Adequate	25	30.1	42.4	100.0
	Total	59	71.1	100.0	
Missing	Data	24	28.9		
Total		83	100.0		

a. Country = Italy

RhinitisasthmaBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	24	28.9	29.3	29.3
	Adequate	58	69.9	70.7	100.0
	Total	82	98.8	100.0	
Missing	Data	1	1.2		
Total		83	100.0		

a. Country = Italy

AtopicdermatitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	40	48.2	49.4	49.4
	Adequate	41	49.4	50.6	100.0
	Total	81	97.6	100.0	
Missing	Data	2	2.4		
Total		83	100.0		

a. Country = Italy

ContactdermatitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	40	48.2	49.4	49.4
	Adequate	41	49.4	50.6	100.0
	Total	81	97.6	100.0	
Missing	Data	2	2.4		
Total		83	100.0		

a. Country = Italy

UrticariaandangioedemaBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	37	44.6	46.8	46.8
	Adequate	42	50.6	53.2	100.0
	Total	79	95.2	100.0	
Missing	Data	4	4.8		
Total		83	100.0		

a. Country = Italy

FoodallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	51	61.4	63.0	63.0
	Adequate	30	36.1	37.0	100.0
	Total	81	97.6	100.0	
Missing	Data	2	2.4		
Total		83	100.0		

a. Country = Italy

DrugallergyimmediateanddelayedBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	39	47.0	50.0	50.0
	Adequate	39	47.0	50.0	100.0
	Total	78	94.0	100.0	
Missing	Data	5	6.0		
Total		83	100.0		

a. Country = Italy

VenomallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	42	50.6	62.7	62.7
	Adequate	25	30.1	37.3	100.0
	Total	67	80.7	100.0	
Missing	Data	16	19.3		
Total		83	100.0		

a. Country = Italy

OccupationalallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	50	60.2	72.5	72.5
	Adequate	19	22.9	27.5	100.0
	Total	69	83.1	100.0	
Missing	Data	14	16.9		
Total		83	100.0		

a. Country = Italy

LatexallergyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	43	51.8	56.6	56.6
	Adequate	33	39.8	43.4	100.0
	Total	76	91.6	100.0	
Missing	Data	7	8.4		
Total		83	100.0		

a. Country = Italy

UnderstandingofthefollowingtermsBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	45	54.2	57.7	57.7
	Adequate	33	39.8	42.3	100.0
	Total	78	94.0	100.0	
Missing	Data	5	6.0		
Total		83	100.0		

a. Country = Italy

UnderstandingofcrossreactivityBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	53	63.9	69.7	69.7
	Adequate	23	27.7	30.3	100.0
	Total	76	91.6	100.0	
Missing	Data	7	8.4		
Total		83	100.0		

a. Country = Italy

BasicmechanismsofallergicnonallergicrhinitisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	45	54.2	57.0	57.0
	Adequate	34	41.0	43.0	100.0
	Total	79	95.2	100.0	
Missing	Data	4	4.8		
Total		83	100.0		

a. Country = Italy

PharmacologictherapyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	34	41.0	42.0	42.0
	Adequate	47	56.6	58.0	100.0
	Total	81	97.6	100.0	
Missing	Data	2	2.4		
Total		83	100.0		

a. Country = Italy

ImmunotherapyBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	57	68.7	71.3	71.3
	Adequate	23	27.7	28.8	100.0
	Total	80	96.4	100.0	
Missing	Data	3	3.6		
Total		83	100.0		

a. Country = Italy

EnvironmentalControlMeasuresBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	49	59.0	61.3	61.3
	Adequate	31	37.3	38.8	100.0
	Total	80	96.4	100.0	
Missing	Data	3	3.6		
Total		83	100.0		

a. Country = Italy

RiskassessmentforanaphylaxisBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	49	59.0	62.0	62.0
	Adequate	30	36.1	38.0	100.0
	Total	79	95.2	100.0	
Missing	Data	4	4.8		
Total		83	100.0		

a. Country = Italy

PrescriptiontrainingofadrenalineBin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	56	67.5	77.8	77.8
	Adequate	16	19.3	22.2	100.0
	Total	72	86.7	100.0	
Missing	Data	11	13.3		
Total		83	100.0		

a. Country = Italy

Withregardtopatientswithapossiblediagnosisofallergic Bin[a]

		Frequency	Percentage	Valid Percentage	Cumulative Percentage
Valid	Inadequate	23	27.7	28.8	28.8
	Adequate	57	68.7	71.3	100.0
	Total	80	96.4	100.0	
Missing	Data	3	3.6		
Total		83	100.0		

a. Country = Italy

Learning and assessment methods preferences and age group crosstabs relationship index

1. Cross Table Age*Which one of the following learning and assessment methods do you prefer?
2. Chi-square
3. Smartphone
4. Tablet
5. Computer

Learning and assessment methods preferences and age group crosstabs relationship index
Frequencies

Statistics

Age			Which one of the following learning and assessment methods do you prefer?	Smartphone	Tablet	Computer
18 - 24	N	Valid	2	3	3	3
		Missing	1	0	0	0
25 - 34	N	Valid	82	83	82	82
		Missing	45	44	45	45
35 - 44	N	Valid	136	136	132	133
		Missing	51	51	55	54
45 - 54	N	Valid	151	153	149	150
		Missing	37	35	39	38
55 - 64	N	Valid	116	119	104	109
		Missing	35	32	47	42
65+	N	Valid	26	21	18	20
		Missing	6	11	14	12

Frequency Table

Which one of the following learning and assessment methods do you prefer?

Age			Frequency	Percentage	Valid Percentage	Cumulative Percentage
18 - 24	Valid	Traditional Learning and Assessment	2	66.7	100.0	100.0
	Missing	Missing	1	33.3		
	Total		3	100.0		

25 - 34	Valid	Traditional Learning and Assessment	48	37.8	58.5	58.5
		E-Learning and on-line assessment	34	26.8	41.5	100.0
		Total	82	64.6	100.0	
	Missing	Missing	45	35.4		
	Total		127	100.0		
35 - 44	Valid	Traditional Learning and Assessment	65	34.8	47.8	47.8
		E-Learning and on-line assessment	71	38.0	52.2	100.0
		Total	136	72.7	100.0	
	Missing	Missing	51	27.3		
	Total		187	100.0		
45 - 54	Valid	Traditional Learning and Assessment	73	38.8	48.3	48.3
		E-Learning and on-line assessment	78	41.5	51.7	100.0
		Total	151	80.3	100.0	
	Missing	Missing	37	19.7		
	Total		188	100.0		
55 - 64	Valid	Traditional Learning and Assessment	77	51.0	66.4	66.4
		E-Learning and on-line assessment	39	25.8	33.6	100.0
		Total	116	76.8	100.0	
	Missing	Missing	35	23.2		
	Total		151	100.0		
65+	Valid	Traditional Learning and Assessment	19	59.4	73.1	73.1
		E-Learning and on-line assessment	7	21.9	26.9	100.0
		Total	26	81.3	100.0	

	Missing	Missing	6	18.8		
	Total		32	100.0		

Smartphone

Age			Frequency	Percentage	Valid Percentage	Cumulative Percentage
18 - 24	Valid	3	1	33.3	33.3	33.3
		4	2	66.7	66.7	100.0
		Total	3	100.0	100.0	
25 - 34	Valid	N/A	2	1.6	2.4	2.4
		1	6	4.7	7.2	9.6
		2	9	7.1	10.8	20.5
		3	9	7.1	10.8	31.3
		4	23	18.1	27.7	59.0
		5	34	26.8	41.0	100.0
		Total	83	65.4	100.0	
	Missing	Data	44	34.6		
	Total		127	100.0		
35 - 44	Valid	N/A	3	1.6	2.2	2.2
		1	11	5.9	8.1	10.3
		2	17	9.1	12.5	22.8
		3	21	11.2	15.4	38.2
		4	40	21.4	29.4	67.6
		5	44	23.5	32.4	100.0
		Total	136	72.7	100.0	
	Missing	Data	51	27.3		
	Total		187	100.0		
45 - 54	Valid	N/A	8	4.3	5.2	5.2
		1	21	11.2	13.7	19.0
		2	26	13.8	17.0	35.9
		3	37	19.7	24.2	60.1
		4	28	14.9	18.3	78.4

		5	33	17.6	21.6	100.0
		Total	153	81.4	100.0	
	Missing	Data	35	18.6		
	Total		188	100.0		
55 - 64	Valid	N/A	10	6.6	8.4	8.4
		1	28	18.5	23.5	31.9
		2	19	12.6	16.0	47.9
		3	24	15.9	20.2	68.1
		4	19	12.6	16.0	84.0
		5	19	12.6	16.0	100.0
		Total	119	78.8	100.0	
	Missing	Data	32	21.2		
	Total		151	100.0		
65+	Valid	1	8	25.0	38.1	38.1
		2	2	6.3	9.5	47.6
		3	7	21.9	33.3	81.0
		4	4	12.5	19.0	100.0
		Total	21	65.6	100.0	
	Missing	Data	11	34.4		
	Total		32	100.0		

Tablet

Age			Frequency	Percentage	Valid Percentage	Cumulative Percentage
18 - 24	Valid	3	1	33.3	33.3	33.3
		4	2	66.7	66.7	100.0
		Total	3	100.0	100.0	
25 - 34	Valid	N/A	6	4.7	7.3	7.3
		1	13	10.2	15.9	23.2
		2	13	10.2	15.9	39.0
		3	14	11.0	17.1	56.1
		4	19	15.0	23.2	79.3

		5	17	13.4	20.7	100.0
		Total	82	64.6	100.0	
	Missing	Data	45	35.4		
	Total		127	100.0		
35 - 44	Valid	N/A	8	4.3	6.1	6.1
		1	11	5.9	8.3	14.4
		2	7	3.7	5.3	19.7
		3	23	12.3	17.4	37.1
		4	39	20.9	29.5	66.7
		5	44	23.5	33.3	100.0
		Total	132	70.6	100.0	
	Missing	Data	55	29.4		
	Total		187	100.0		
45 - 54	Valid	N/A	6	3.2	4.0	4.0
		1	9	4.8	6.0	10.1
		2	12	6.4	8.1	18.1
		3	29	15.4	19.5	37.6
		4	46	24.5	30.9	68.5
		5	47	25.0	31.5	100.0
		Total	149	79.3	100.0	
	Missing	Data	39	20.7		
	Total		188	100.0		
55 - 64	Valid	N/A	11	7.3	10.6	10.6
		1	11	7.3	10.6	21.2
		2	4	2.6	3.8	25.0
		3	23	15.2	22.1	47.1
		4	29	19.2	27.9	75.0
		5	26	17.2	25.0	100.0
		Total	104	68.9	100.0	
	Missing	Data	47	31.1		
	Total		151	100.0		
65+	Valid	1	8	25.0	44.4	44.4

		2	1	3.1	5.6	50.0
		3	4	12.5	22.2	72.2
		4	2	6.3	11.1	83.3
		5	3	9.4	16.7	100.0
		Total	18	56.3	100.0	
	Missing	Data	14	43.8		
	Total		32	100.0		

Computer

Age			Frequency	Percentage	Valid Percentage	Cumulative Percentage
18 - 24	Valid	3	1	33.3	33.3	33.3
		4	2	66.7	66.7	100.0
		Total	3	100.0	100.0	
25 - 34	Valid	N/A	2	1.6	2.4	2.4
		1	4	3.1	4.9	7.3
		2	5	3.9	6.1	13.4
		3	8	6.3	9.8	23.2
		4	26	20.5	31.7	54.9
		5	37	29.1	45.1	100.0
		Total	82	64.6	100.0	
	Missing	Data	45	35.4		
	Total		127	100.0		
35 - 44	Valid	N/A	2	1.1	1.5	1.5
		2	4	2.1	3.0	4.5
		3	15	8.0	11.3	15.8
		4	43	23.0	32.3	48.1
		5	69	36.9	51.9	100.0
		Total	133	71.1	100.0	
	Missing	Data	54	28.9		
	Total		187	100.0		
45 - 54	Valid	N/A	1	0.5	0.7	0.7

		1	1	0.5	0.7	1.3
		2	7	3.7	4.7	6.0
		3	14	7.4	9.3	15.3
		4	35	18.6	23.3	38.7
		5	92	48.9	61.3	100.0
		Total	150	79.8	100.0	
	Missing	Data	38	20.2		
	Total		188	100.0		
55 - 64	Valid	N/A	4	2.6	3.7	3.7
		1	2	1.3	1.8	5.5
		2	3	2.0	2.8	8.3
		3	19	12.6	17.4	25.7
		4	30	19.9	27.5	53.2
		5	51	33.8	46.8	100.0
		Total	109	72.2	100.0	
	Missing	Data	42	27.8		
	Total		151	100.0		
65+	Valid	1	4	12.5	20.0	20.0
		2	1	3.1	5.0	25.0
		3	2	6.3	10.0	35.0
		4	3	9.4	15.0	50.0
		5	10	31.3	50.0	100.0
		Total	20	62.5	100.0	
	Missing	Data	12	37.5		
	Total		32	100.0		

Cross Tables

Summary of case preocessing

	Cases		
Valid	Missing	Total	

	N	Percentage	N	Percentage	N	Percentage
Age * Which one of the following learning and assessment methods do you	513	74.6%	175	25.4%	688	100.0%

Cross Table Age*Which one of the following learning and assessment methods do you prefer?

			Which one of the following learning and assessment methods do you prefer?		
			Traditional Learning and Assessment	E-Learning and on-line assessment	Total
Age	18 - 24	n	2	0	2
		% within Age	100.0%	0.0%	100.0%
	25 - 34	n	48	34	82
		% within Age	58.5%	41.5%	100.0%
	35 - 44	n	65	71	136
		% within Age	47.8%	52.2%	100.0%
	45 - 54	n	73	78	151
		% within Age	48.3%	51.7%	100.0%
	55 - 64	n	77	39	116
		% within Age	66.4%	33.6%	100.0%
	65+	n	19	7	26
		% within Age	73.1%	26.9%	100.0%
Total		n	284	229	513
		% within Age	55.4%	44.6%	100.0%

Chi-square

	Value	df	Asymptotic significance (bilateral)

Chi-square Pearson	17,107[a]	5	0.004
Likelihood ratio	18.132	5	0.003
Lineal by linear association	3.616	1	0.057
N Valid Cases	513		

a. 2 boxes (16,7%) expected a count less than 5. The minimum expected count is ,89.

Unidirectional

Descriptives

Smartphone

	N	Mean	Standard deviation	Standar error	95% level of the confidence for the mean		Minimum	Maximum
					Lower Limit	Upper Limit		
18 - 24	3	3.67	0.577	0.333	2.23	5.10	3	4
25 - 34	81	3.86	1.282	0.142	3.58	4.15	1	5
35 - 44	133	3.67	1.283	0.111	3.45	3.89	1	5
45 - 54	145	3.18	1.357	0.113	2.96	3.40	1	5
55 - 64	109	2.83	1.437	0.138	2.56	3.11	1	5
65+	21	2.33	1.197	0.261	1.79	2.88	1	4
Total	492	3.32	1.395	0.063	3.19	3.44	1	5

ANOVA

Smartphone

	Sum of squares	gl	Least square mean	F	Sig.
Between groups	89.520	5	17.904	10.040	0.000
Within groups	866.649	486	1.783		
Total	956.169	491			

Pruebas post hoc

Multiple Comparisons

Dependent Variable: Smartphone

Bonferroni

(I) Age		Means Diferences (I-J)	Standar error	Sig.	95% level of confidence	
					Lower Limit	Upper Limit
18 - 24	25 - 34	-0.198	0.785	1.000	-2.51	2.12
	35 - 44	-0.003	0.780	1.000	-2.30	2.30
	45 - 54	0.487	0.779	1.000	-1.81	2.78
	55 - 64	0.832	0.782	1.000	-1.47	3.14
	65+	1.333	0.824	1.000	-1.10	3.76
25 - 34	18 - 24	0.198	0.785	1.000	-2.12	2.51
	35 - 44	0.195	0.188	1.000	-0.36	0.75
	45 - 54	,685*	0.185	0.004	0.14	1.23
	55 - 64	1,029*	0.196	0.000	0.45	1.61
	65+	1,531*	0.327	0.000	0.57	2.50
35 - 44	18 - 24	0.003	0.780	1.000	-2.30	2.30
	25 - 34	-0.195	0.188	1.000	-0.75	0.36
	45 - 54	,490*	0.160	0.036	0.02	0.96
	55 - 64	,834*	0.173	0.000	0.33	1.34
	65+	1,336*	0.314	0.000	0.41	2.26
45 - 54	18 - 24	-0.487	0.779	1.000	-2.78	1.81
	25 - 34	-,685*	0.185	0.004	-1.23	-0.14
	35 - 44	-,490*	0.160	0.036	-0.96	-0.02
	55 - 64	0.344	0.169	0.636	-0.15	0.84
	65+	0.846	0.312	0.103	-0.07	1.77
55 - 64	18 - 24	-0.832	0.782	1.000	-3.14	1.47
	25 - 34	-1,029*	0.196	0.000	-1.61	-0.45

	35 - 44	-,834*	0.173	0.000	-1.34	-0.33
	45 - 54	-0.344	0.169	0.636	-0.84	0.15
	65+	0.502	0.318	1.000	-0.44	1.44
65+	18 - 24	-1.333	0.824	1.000	-3.76	1.10
	25 - 34	-1,531*	0.327	0.000	-2.50	-0.57
	35 - 44	-1,336*	0.314	0.000	-2.26	-0.41
	45 - 54	-0.846	0.312	0.103	-1.77	0.07
	55 - 64	-0.502	0.318	1.000	-1.44	0.44

*. The mean difference is significat at level 0.05.

Unidirectional

Descriptives

Tablet

	N	Mean	Standard deviation	Standar error	95% level of the confidence for the mean		Minimum	Maximum
					Lower Limit	Upper Limit		
18 - 24	3	3.67	0.577	0.333	2.23	5.10	3	4
25 - 34	76	3.18	1.411	0.162	2.86	3.51	1	5
35 - 44	124	3.79	1.238	0.111	3.57	4.01	1	5
45 - 54	143	3.77	1.179	0.099	3.57	3.96	1	5
55 - 64	93	3.59	1.270	0.132	3.33	3.85	1	5
65+	18	2.50	1.581	0.373	1.71	3.29	1	5
Total	457	3.59	1.300	0.061	3.47	3.71	1	5

ANOVA

Tablet

	Sum of squares	gl	Least square mean	F	Sig.
Between groups	43.488	5	8.698	5.396	0.000

Within groups	726.994	451	1.612		
Total	770.481	456			

Pruebas post hoc

Múltiple comparisons

Dependent variable: Tablet

Bonferroni

(I) Age		Means Diferences (I-J)	Standar error	Sig.	95% level of confidence	
					Lower Limit	Upper Limit
18 - 24	25 - 34	0.482	0.747	1.000	-1.72	2.69
	35 - 44	-0.124	0.742	1.000	-2.31	2.07
	45 - 54	-0.103	0.741	1.000	-2.29	2.08
	55 - 64	0.075	0.745	1.000	-2.12	2.27
	65+	1.167	0.792	1.000	-1.17	3.50
25 - 34	18 - 24	-0.482	0.747	1.000	-2.69	1.72
	35 - 44	-,606*	0.185	0.017	-1.15	-0.06
	45 - 54	-,585*	0.180	0.019	-1.12	-0.05
	55 - 64	-0.407	0.196	0.580	-0.99	0.17
	65+	0.684	0.333	0.606	-0.30	1.67
35 - 44	18 - 24	0.124	0.742	1.000	-2.07	2.31
	25 - 34	,606*	0.185	0.017	0.06	1.15
	45 - 54	0.021	0.156	1.000	-0.44	0.48
	55 - 64	0.199	0.174	1.000	-0.32	0.71
	65+	1,290*	0.320	0.001	0.35	2.24
45 - 54	18 - 24	0.103	0.741	1.000	-2.08	2.29
	25 - 34	,585*	0.180	0.019	0.05	1.12
	35 - 44	-0.021	0.156	1.000	-0.48	0.44
	55 - 64	0.178	0.169	1.000	-0.32	0.68
	65+	1,269*	0.318	0.001	0.33	2.21

55 - 64	18 - 24	-0.075	0.745	1.000	-2.27	2.12
	25 - 34	0.407	0.196	0.580	-0.17	0.99
	35 - 44	-0.199	0.174	1.000	-0.71	0.32
	45 - 54	-0.178	0.169	1.000	-0.68	0.32
	65+	1,091*	0.327	0.014	0.13	2.06
65+	18 - 24	-1.167	0.792	1.000	-3.50	1.17
	25 - 34	-0.684	0.333	0.606	-1.67	0.30
	35 - 44	-1,290*	0.320	0.001	-2.24	-0.35
	45 - 54	-1,269*	0.318	0.001	-2.21	-0.33
	55 - 64	-1,091*	0.327	0.014	-2.06	-0.13

*. The mean difference is significat at level 0.05.

Unidirectional

Descriptives

Computer

	N	Mean	Standard deviation	Standar error	95% level of the confidence for the mean		Minimum	Maximum
					Lower Limit	Upper Limit		
18 - 24	3	3.67	0.577	0.333	2.23	5.10	3	4
25 - 34	80	4.09	1.127	0.126	3.84	4.34	1	5
35 - 44	131	4.35	0.803	0.070	4.21	4.49	2	5
45 - 54	149	4.41	0.893	0.073	4.26	4.55	1	5
55 - 64	105	4.19	0.962	0.094	4.00	4.38	1	5
65+	20	3.70	1.625	0.363	2.94	4.46	1	5
Total	488	4.26	0.976	0.044	4.17	4.35	1	5

ANOVA

Computer

	Sum of squares	gl	Least square mean	F	Sig.
Between groups	14.630	5	2.926	3.139	0.008
Within groups	449.319	482	0.932		
Total	463.949	487			

Pruebas post hoc

Multiple comparisons

Dependent Variable: Computer

Bonferroni

(I) Age		Means Diferences (I-J)	Standar error	Sig.	95% level of confidence	
					Lower Limit	Upper Limit
18 - 24	25 - 34	-0.421	0.568	1.000	-2.10	1.25
	35 - 44	-0.684	0.564	1.000	-2.35	0.98
	45 - 54	-0.743	0.563	1.000	-2.40	0.92
	55 - 64	-0.524	0.565	1.000	-2.19	1.14
	65+	-0.033	0.598	1.000	-1.80	1.73
25 - 34	18 - 24	0.421	0.568	1.000	-1.25	2.10
	35 - 44	-0.264	0.137	0.823	-0.67	0.14
	45 - 54	-0.322	0.134	0.248	-0.72	0.07
	55 - 64	-0.103	0.143	1.000	-0.53	0.32
	65+	0.388	0.241	1.000	-0.32	1.10
35 - 44	18 - 24	0.684	0.564	1.000	-0.98	2.35
	25 - 34	0.264	0.137	0.823	-0.14	0.67
	45 - 54	-0.058	0.116	1.000	-0.40	0.28
	55 - 64	0.161	0.126	1.000	-0.21	0.53
	65+	0.651	0.232	0.078	-0.03	1.33
45 - 54	18 - 24	0.743	0.563	1.000	-0.92	2.40
	25 - 34	0.322	0.134	0.248	-0.07	0.72

	35 - 44	0.058	0.116	1.000	-0.28	0.40
	55 - 64	0.219	0.123	1.000	-0.14	0.58
	65+	,709*	0.230	0.032	0.03	1.39
55 - 64	18 - 24	0.524	0.565	1.000	-1.14	2.19
	25 - 34	0.103	0.143	1.000	-0.32	0.53
	35 - 44	-0.161	0.126	1.000	-0.53	0.21
	45 - 54	-0.219	0.123	1.000	-0.58	0.14
	65+	0.490	0.236	0.568	-0.20	1.19
65+	18 - 24	0.033	0.598	1.000	-1.73	1.80
	25 - 34	-0.388	0.241	1.000	-1.10	0.32
	35 - 44	-0.651	0.232	0.078	-1.33	0.03
	45 - 54	-,709*	0.230	0.032	-1.39	-0.03
	55 - 64	-0.490	0.236	0.568	-1.19	0.20

*. The mean difference is significat at level 0.05.

Education, learning and assessment methods crosstabs and country relationship index

1. Awareness of knowledge about GP guidelines which include guidelines for referral and country
2. Use of GP guidelines which include guidelines for referral and country
3. Awareness of the EAACI competencies document for allied health professionals for allergy and country
4. Access to allergy investigations in your Primary Care facility and country
5. Access to immuotherapy in your practice or by referring to a specialised service and country
6. Prefered learning and assessment methods and country (Traditional/E-Learning) and country
7. Smartphone and country
8. Tablet and country
9. Computer and country

Cross Tables

Are you aware of the GP guidelines which include guidelines for referral in your country? * Country

Cross Table

			Country					
			United Kingdom	Spain	Netherlands	Poland	Italy	Total
Are you aware of the GP guidelines which include guidelines for referral in your country?	No	n	141	74	2	16	10	243
		% within country	54.2%	69.2%	3.8%	38.1%	33.3%	49.4%
	Yes	n	119	33	51	26	20	249
		% within country	45.8%	30.8%	96.2%	61.9%	66.7%	50.6%
Total		n	260	107	53	42	30	492
		% within country	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

chi-square

	Value	df	Asymptotic significance (bilateral)
Chi-square Pearson	68,525[a]	4	0.000
Likelihood ratio	80.153	4	0.000
Lineal by linear association	19.646	1	0.000
N Valid Cases	492		

a. 0 boxes (0,0%) expected a count less than 5. The minimum count expected count is 14,82.

Do you use these guidelines? * Country

Cross Table

			Country					
			United Kingdom	Spain	Netherlands	Poland	Italy	Total
Do you use these guidelines?	No	n	32	1	12	5	8	58
		% within country	27.1%	3.0%	23.5%	19.2%	32.0%	22.9%
	Yes	n	86	32	39	21	17	195
		% within country	72.9%	97.0%	76.5%	80.8%	68.0%	77.1%
Total		n	118	33	51	26	25	253
		% within country	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

chi-square

	Value	df	Asymptotic significance (bilateral)
Chi-square Pearson	9,943[a]	4	0.041
Likelihood ratio	13.074	4	0.011
Lineal by linear association	0.001	1	0.979
N Valid Cases	253		

a. 0 boxes (0,0%) expected a count less than 5. The minimum count expected is 5,73.

Are you aware of the EAACI competencies document for allied health professionals for allergy? * Country

Cross table

			Country

			United Kingdom	Spain	Netherlands	Poland	Italy	Total
Are you aware of the EAACI competencies document for allied health professionals for	No	n	210	99	52	38	55	454
		% within country	82.0%	92.5%	98.1%	90.5%	94.8%	88.0%
	Yes	n	46	8	1	4	3	62
		% within country	18.0%	7.5%	1.9%	9.5%	5.2%	12.0%
Total		n	256	107	53	42	58	516
		% within country	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

chi-square

	Value	df	Asymptotic significance (bilateral)
Chi-square Pearson	18,626[a]	4	0.001
Likelihood ratio	21.042	4	0.000
Lineal by linear association	11.386	1	0.001
N Valid Cases	516		

a. 0 boxes (0,0%) expected a count less than 5. The n mínimum expected is 5,05.

Do you have access to allergy investigations in your Primary Care facility? * Country

Cross table

			Country				
			United Kingdom	Netherlands	Poland	Italy	Total
Do you have access to allergy investigations in	No	n	130	10	40	65	245
		% within country	50.8%	18.9%	95.2%	90.3%	57.9%

your Primary Care facility?	Yes	n	126	43	2	7	178
		% within country	49.2%	81.1%	4.8%	9.7%	42.1%
Total		n	256	53	42	72	423
		% within country	100.0%	100.0%	100.0%	100.0%	100.0%

chi-square

	Value	df	Asymptotic significance (bilateral)
Chi-square Pearson	93,445[a]	3	0.000
Likelihood ratio	107.572	3	0.000
Lineal by linear association	36.246	1	0.000
N Valid Cases	423		

a. 0 boxes (0,0%) expected a count less than 5. The minimum count expected is 17,67.

Cross Tables

Do you have access to immuotherapy in your practice or by referring to a specialised service? * Country

Cross table

			Country					
			United Kingdom	Spain	Netherlands	Poland	Italy	Total
Do you have access to immu0therapy in your practice or by referring to a	No	n	124	42	3	23	66	258
		% within country	49.8%	45.2%	5.7%	54.8%	82.5%	49.9%
	Yes	n	125	51	50	19	14	259

referring to a specialised	% within country	50.2%	54.8%	94.3%	45.2%	17.5%	50.1%
Total	n	249	93	53	42	80	517
	% within country	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

chi-square

	Value	df	Asymptotic significance (bilateral)
Chi-square Pearson	76,734[a]	4	0.000
Likelihood ratio	88.380	4	0.000
Lineal by linear association	12.048	1	0.001
N Valid Cases	517		

a. 0 boxes (0,0%) expected a count less than 5. The minimum count expected is 20,96.

Which one of the following learning and assessment methods do you prefer? * Country

Cross tableTabla cruzada

			Country					
			United Kingdom	Spain	Netherlands	Poland	Italy	Total
Which one of the following learning and assessment methods do you prefer?	Traditional Learning and Assessment	n	123	46	26	30	59	284
		% within country	49.6%	49.5%	49.1%	71.4%	74.7%	55.1%
	E-Learning and on-line assessment	n	125	47	27	12	20	231
		% within country	50.4%	50.5%	50.9%	28.6%	25.3%	44.9%
Total		n	248	93	53	42	79	515
		% within country	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

chi-cuadrado

	Value	df	Asymptotic significance (bilateral)
Chi-square Pearson	21,790[a]	4	0.000
Likelihood ratio	22.675	4	0.000
Lineal by linear association	17.460	1	0.000
N Valid Cases	515		

a. 0 boxes (0,0%) expected a count less than 5. The minimum count expected is 18,84.

Smartphone * Country

Cross Table

			Country					
			United Kingdom	Spain	Netherlands	Poland	Italy	Total
Smartphone	N/A	n	15	8	0	0	0	23
		% within country	6.0%	7.6%	0.0%	0.0%	0.0%	4.5%
	1	n	37	5	12	2	18	74
		% within country	14.9%	4.8%	24.5%	4.8%	25.0%	14.3%
	2	n	33	16	12	3	9	73
		% within country	13.3%	15.2%	24.5%	7.1%	12.5%	14.1%
	3	n	53	15	11	4	16	99
		% within country	21.4%	14.3%	22.4%	9.5%	22.2%	19.2%
	4	n	52	29	9	12	15	117
		% within country	21.0%	27.6%	18.4%	28.6%	20.8%	22.7%
	5	n	58	32	5	21	14	130

	% within country	23.4%	30.5%	10.2%	50.0%	19.4%	25.2%
Total	n	248	105	49	42	72	516
	% within country	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

chi-square

	Value	df	Asymptotic significance (bilateral)
Chi-square Pearson	59,481[a]	20	0.000
Likelihood ratio	66.952	20	0.000
Lineal by linear association	0.567	1	0.452
N Valid Cases	516		

a. 4 boxes (13,3%) expected a count less than 5. The minimum count expected is 1,87.

Tablet * Country

Cross table

			Country					
			United Kingdom	Spain	Netherlands	Poland	Italy	Total
Tablet	N/A	n	21	10	0	0	0	31
		% within country	8.5%	9.5%	0.0%	0.0%	0.0%	6.3%
	1	n	10	2	4	19	17	52
		% within country	4.0%	1.9%	7.8%	45.2%	39.5%	10.6%
	2	n	22	6	2	6	1	37
		% within country	8.9%	5.7%	3.9%	14.3%	2.3%	7.6%
	3	n	50	23	9	6	6	94

		% within country	20.2%	21.9%	17.6%	14.3%	14.0%	19.2%
	4	n	64	35	24	5	10	138
		% within country	25.8%	33.3%	47.1%	11.9%	23.3%	28.2%
	5	n	81	29	12	6	9	137
		% within country	32.7%	27.6%	23.5%	14.3%	20.9%	28.0%
Total		n	248	105	51	42	43	489
		% within country	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

chi-square

	Value	df	Asymptotic significance (bilateral)
Chi-square Pearson	137,041[a]	20	0.000
Likelihood ratio	118.103	20	0.000
Lineal by linear association	13.400	1	0.000
N Valid Cases	489		

a. 8 boxes (26,7%) expected a count less than 5. The minimum count expected is 2,66.

Computer * Country

Cross table

			Country					
			United Kingdom	Spain	Netherlands	Poland	Italy	Total
Computer	N/A	n	3	6	0	0	0	9
		% within country	1.2%	5.7%	0.0%	0.0%	0.0%	1.8%
	1	n	3	0	0	2	6	11

		% within country	1.2%	0.0%	0.0%	4.8%	11.5%	2.2%
	2	n	8	6	2	3	1	20
		% within country	3.2%	5.7%	3.8%	7.1%	1.9%	4.0%
	3	n	34	10	2	6	7	59
		% within country	13.7%	9.5%	3.8%	14.3%	13.5%	11.8%
	4	n	64	34	23	12	6	139
		% within country	25.8%	32.4%	44.2%	28.6%	11.5%	27.9%
	5	n	136	49	25	19	32	261
		% within country	54.8%	46.7%	48.1%	45.2%	61.5%	52.3%
Total		n	248	105	52	42	52	499
		% within country	100.0%	100.0%	100.0%	100.0%	100.0%	100.0%

chi-square

	Value	df	Asymptotic significance (bilateral)
Chi-square Pearson	58,979[a]	20	0.000
Likelihood ratio	52.856	20	0.000
Lineal by linear association	1.182	1	0.277
N Valid Cases	499		

a. 14 boxes (46,7%) expected a count less than 5. The minimum count expected is ,76.